Document:

QuickLinks
 -- Click here to rapidly navigate through this document
  

 
 

Exhibit 10.17    
    

 
 

LICENCE AGREEMENT    
    

by and between

GENTIUM S.p.A.  

        (Fiscal Code and Vat Code No. 02098100130), with legal offices in Piazza XX Settembre, no2, 22079 Villa Guardia (CO), acting through its President
and Managing Director Ms. Laura Iris Ferro and domiciled for his office for the purposes of this agreement at the offices of the Company (hereinafter referred to as "GENTIUM") 

and  

 CRINOS S.p.A.  

        (Fiscal Code and Vat Code No. 03481280968), with legal offices in Milan, via Pavia 6, acting through its Managing Director Mr. Enrique Hausermann and domiciled
for his office for the purposes of this agreement at the offices of the Company (hereinafter called "CRINOS"). 

DEFINITIONS  

        For the purposes of this Agreement, all capitalised terms used herein, other than proper nouns, are defined as follows: 

	•
	"Affiliate" means, with respect to each party, any company owned, controlled, or controlling, directly or indirectly, to the
extent of fifty percent (50%) or more of the shares or outstanding securities of either Party;

	•
	"A.I.C." shall mean the marketing authorisations relevant to the Product issued by the MOH.

	•
	"Defibrotide" means a poli-desoxi-ribonucleotide extracted from swine mucose;

	•
	"Know-how" means the whole of technical and scientific information, which are secret and substantial;

	•
	"MOH" means the Italian Ministry of Health;

	•
	"Patents" means the patents described in Exhibit A;

	•
	"Product" means the pharmaceutical products for human use only, containing Defibrotide as the sole therapeutically active
ingredient for the forms defined in the Exhibit B, and being commercialised under the Trademark "Noravid";

	•
	"Territory" means Italy, San Marino and Città del Vaticano;

	•
	"Net Sales" means the sales of the Product as invoiced in the Territory, by CRINOS, less normal trade returns, cash and trade
discounts.

	•
	"Accounting Period" shall mean the quarters ending 31st March, 30th June, 30th
September and 31st December. 

 WITNESSETH  

	A.
	WHEREAS, GENTIUM is the sole owner of the Patent; 

1

 

	B.
	WHEREAS GENTIUM has already granted to CRINOS, on May 17th, 2002, a semi exclusive gratuitous license (the
"Prociclide Contract") in order to distribute, promote and sell the Product containing Defibrotide within the Territory, under the trademark "Prociclide".

	C.
	WHEREAS CRINOS, in the "Prociclide Contract", acknowledged that Sirton Pharmaceuticals S.p.A. (formerly known as CRINOS Industria
Farmacobiologica S.p.A) entered into a semi exclusive license and supply contract with Roussel Maestretti S.p.A. (now Aventis) on December 20th, 1985 (the "Aventis Contract") pursuant to which
the licensee granted a semi-exclusive license to Aventis for the sale and commercialisation in Italy of the products containing the active ingredient "Defibrotide" under the trademark
"Noravid", owned by Aventis;

	D.
	WHEREAS CRINOS and Aventis have reached an agreement in order for CRINOS to purchase the trademark "Noravid" owned by Aventis and the
relevant A.I.C.;

	E.
	WHEREAS GENTIUM has given its consent to Aventis, pursuant to the Aventis contract, in order to sell the trademark "Noravid" and the
relevant AIC to CRINOS;

	F.
	WHEREAS GENTIUM and Aventis has agreed to terminate the Aventis contract, effective from the publication on the Gazzetta Ufficiale of
the Decree of transfer of the A.I.C. to CRINOS;

	G.
	WHEREAS CRINOS S.p.A. as new owner of the Italian Trade Mark "Noravid" formerly owned by Aventis and of A.I.C. 02608052 (capsules) and
026086025 (ampoules) now wishes to obtain the rights to distribute, promote and sell the Products containing Defibrotide within the Territory also under the trade mark "Noravid";

	H.
	WHEREAS, GENTIUM is willing to grant the right to promote, market, sell and distribute the Products to CRINOS in the Territory upon the
following terms and conditions: 

        NOW,
THEREFORE, the parties agree as follows: 

ARTICLE 1—WHEREAS CLAUSES AND ANNEXES  

        The definitions, whereas clauses and the annexes shall be considered as an integral part of this agreement. 

ARTICLE 2—APPOINTMENT  

	2.1.
	GENTIUM
hereby grants CRINOS with a non-exclusive license to use the know-how and Patent to market under the trade mark "Noravid", in the Territory, the
Products containing the patented active ingredient in the current therapeutic indications and also with regard to the indications the MOH will grant within the procedure of revision of the Product.

	2.2.
	It
is understood that the execution of the present license contract will not affect the right of GENTIUM to grant to a third party a semi-exclusive license pursuant to
article 2.1. of the "Prociclide Contract" entered with CRINOS on May 17th, 2002.

	2.3.
	CRINOS
undertake to have the Products manufactured and supplied exclusively by Sirton Pharmaceuticals S.p.A. With regard to the terms and conditions for such manufacturing and
supply, the parties refer to the production agreement stipulated between CRINOS and Sirton Pharmaceuticals S.p.A. on 17 May 2002 (the "Manufacturing and Supply Agreement"), which shall apply
also to the Products commercialised under the trademark "Noravid". It is however understood that, with regard to the prices and payment terms, clause 4.5, first part, of the Manufacturing and
Supply Agreement shall not apply to "Noravid". Such product, being related to "Defibrotide", as well as the product commercialised under the trademark "Prociclide", shall be 

2

 

regulated
by the second part of article 4.5 of the Manufacturing and Supply Agreement, providing for an yearly updating of the price, according to the ISTAT-Index and for a revision of the
price, every two years, made by the Parties in good faith, in consideration of any change in the prices of components and materials, of the utilities and personnel and Quality costs. 

	2.4.
	In
consideration of the consent given by GENTIUM to Aventis, pursuant to the Aventis Contract, in order to sell the trademark "Noravid" and the relevant AIC to CRINOS and of the
consequent renunciation by GENTIUM to all the rights on the trademark and AIC, the Parties agree that, CRINOS shall pay to GENTIUM a 3% (three percent) royalty on Net Sales. Such payment will start
once the AIC has been granted to CRINOS as per Article 11.1.

	2.5.
	The
royalties due to CRINOS pursuant to Article 2.4 here above shall be paid within 60 (sixty) days after the end of each successive Accounting Period, in respect of the Net
Sales made in that Accounting Period.

	2.6.
	In
consideration of the above, SIRTON declares to waive to any eventual further right to be compensated/indemnified for the termination of the Aventis Contract, in particular with
reference to Article 2.2 of the Prociclide Contract. 

ARTICLE 3—SUPPLY OF SCIENTIFIC/TECHNICAL INFORMATION, KNOW HOW AND ASSISTANCE  

	3.1.
	GENTIUM
agrees to provide to CRINOS the existing technical information, know how and scientific assistance, reasonably required by CRINOS to market, promote and sell the Product
according to the present Agreement.

	3.2.
	Personnel
designated by CRINOS shall be given a reasonable opportunity to study the Product and its scientific data and to discuss such information with GENTIUM representatives
(experts, specialists). CRINOS shall let GENTIUM know in great advance, in writing, the names, interests and qualifications of the aforesaid personnel in order for GENTIUM to have ample time to
organize and provide the reasonable information needed. 

3

  

	3.3.
	CRINOS
shall not engage in any development activities, including, without limitation, clinical trials, with respect to the Product without the prior written consent of GENTIUM.

	3.4.
	Should
CRINOS, for any reason or event, know or obtain any know how and/or any innovation apt to be patented, it is understood that GENTIUM will be the only owner of any rights
deriving from such know how or innovations.

	3.5.
	The
PARTIES shall inform each other promptly (for serious and unexpected ADR'S within 24 hours from knowledge) of all knowledge and of any new findings reflecting on the
safety of Product which come to either Party's attention during the term of this Agreement.

	3.6.
	Each
Party agrees to provide the other with all the necessary, reasonable, requested assistance in order to comply with all post approval, including but not limited to Periodic
Safety Update Report.

	3.7.
	CRINOS
shall maintain at all time an effective tracking system of recall of the Product within the territory. 

ARTICLE 4—PROMOTION AND CLINICAL STUDIES  

	4.1.
	CRINOS
will engage its best efforts to develop the sales of the Product in the Territory.

	4.2.
	CRINOS
shall promote the Product using only sales, advertising and promotional materials which are compatible with the determination of the Product indications, and the use of which
does not violate any applicable law. In any case CRINOS will submit any promotional material to GENTIUM in advance and GENTIUM will have the right to approve it. In order to ensure consistency of
Promotional Material with the scientific and clinical profile of the Product, CRINOS shall only use Promotional Materials which have been approved in writing by GENTIUM as to the accuracy of their
technical, scientific and medical content. GENTIUM shall provide CRINOS with motivated reasons in case of its refusal. 

ARTICLE 5—OBLIGATIONS DERIVING FROM LAW DECREE No. 196/2003  

        The Parties undertake and guarantee that they will comply with the provisions contained in Law Decree No. 196 of June 30, 2003, regarding the
protection of personal data, making any communication which should be necessary and obtaining any authorisation of the Guarantor which should become necessary for the execution of this agreement. 

ARTICLE 6—CONFIDENTIALITY  

	6.1.
	Neither
party shall disclose any information received from the other party or an Affiliate of the other party pursuant to this Agreement or to any previous agreements between the
parties or their Affiliates relating to the Product without the other party's written consent. Such information is confidential and proprietary. 

This
obligation of confidentiality does not apply to: 

	1)
	information
which is or was known to the receiving party at the time of its disclosure pursuant to this Agreement or any previous agreement as established by such party's or its
Affiliates' written records;

	2)
	information
disclosed to the receiving party by a third party (other than its Affiliates) having the right to disclose such information;

	3)
	information
which becomes patented, published or otherwise part of the public domain as a result of acts of the disclosing party or of a third party obtaining such information and
having the right to disclose the same. 

4

 

	4)
	Information
that have to be disclosed by virtue of any applicable disposition of law.

	6.2.
	Each
party agrees that it shall not use confidential information obtained as set forth in Article 6 above for any purpose other than that indicated in this Agreement without
the prior written approval of the other party. This obligation is not breached by the sale of Units and Samples embodying such information., pursuant of the terms of this agreement. 

The
parties agree that the provision set forth in this article 6 survives after expiration and/or termination for any reason of this agreement until the confidential information becomes of
public knowledge, without any breach of this clause made by CRINOS. 

ARTICLE 7—RELATIONSHIP  

        The parties are independent contractors. Neither party is an employee, officer, agent, partner, business representative or legal representative of or joint
venture with the other party. Neither party has authority to assume any obligation on behalf of the other party and shall not hold out to third parties that it has any authority to act on the other
party's behalf. Neither party shall take any action that might mislead or confuse third parties in this regard. Each party shall be responsible for its own expenses and shall not incur expenses for
the other party's account unless expressly authorised in writing to do so by the other party. 

ARTICLE 8—DISCLOSURES  

	8.1.
	Each
party agrees that, except as may be required by law, it shall not disclose the substance or details of this Agreement, except as required to disclose to any of its Affiliates in
the performance of its obligations or exercise of any of its rights hereunder, without the prior written consent of the other party. In cases in which disclosure may be required by law, the disclosing
party, prior to such disclosure, shall promptly notify the non-disclosing party of the contents of the proposed disclosure.

	8.2.
	Consistent
with applicable law, the non-disclosing party shall have the right to recommend/suggest reasonable changes or objections to the disclosure to protect its
interests. The disclosing party shall not unreasonably refuse to include such changes in its disclosure. 

ARTICLE 9—COMPLIANCE WITH LAW  

        Each of the party shall not take any action which would, or fail to take any action where such failure would, directly or indirectly result in or constitute a
violation by CRINOS or GENTIUM of any applicable law, treaty, ruling or regulation. In performing its obligations under this Agreement, neither party nor any person acting on its behalf shall make,
directly or indirectly, any offer or promise or authorise bribes, kickback, payoff or any other payment or gift intended to improperly influence an agent, government official, political party or
candidate for public office to exercise their discretionary authority or influence in order to assist in the sale, marketing, promotion, importation, licensing or distribution of the Products. 

ARTICLE 10 TERM (NATURAL EXPIRATION) AND TERMINATION  

	10.1.
	The
present Agreement will be effective and binding for the Parties starting from the date of the publication on the Gazzetta Ufficiale of the transfer decree of the AIC n. 02608052
(capsules) and 026086025 (ampoules) to CRINOS.

	10.2.
	Unless
terminated by either party in accordance with the provision of clause 10.3, this agreement shall remain valid and in force at least till the expiration of the Patent
on the Product. Notwithstanding the above this agreement shall remain valid between the parties at the same 

5

 

conditions
for renewable periods of 3 years each in case the market life or the Product will be deemed in good faith by the Parties to survive after the expiration of the Patent. 

	10.3.
	Without
any prejudice to the other cases of early termination set forth in this Agreement, this Agreement may be also terminated prior to the expiration of the term set forth in
Article 10.2 in the event one of the following conditions occur:

	1)
	either
party's giving 60 days' notice to the other party of a stated breach of any of the terms and conditions of this Agreement by the other party and the other party's failure
to cure its breach within the 60 days' notice period provided.

	2)
	either
party's giving 60 days' notice to the other party if an event of force majeure under Article 15 continues for more than twelve (12) months, it is clearly
understood between the parties that this clause can be applied only under request of the party that is not affected by the event of force majeure;

	3)
	without
notice, in case of communication from either party to the other party in the case of any declaration of bankruptcy or insolvency, appointment of a receiver by a court of
competent jurisdiction, assignment for the benefit of creditors, or institution of liquidation proceeding by or against the other party;

	10.4.
	GENTIUM
will have the right to terminate this agreement in case CRINOS ceases to have the Product manufactured by Sirton Pharmaceuticals S.p.A. except that GENTIUM consents to
change the manufacturer, being however understood that such right to terminate the contract is conditioned to the fact that Sirton Pharmaceuticals S.p.A. will respect the price and payment terms
provided in Section 4.1 and 4.5 second paragraph of the Production Agreement between CRINOS and Sirton Pharmaceuticals S.p.A..

	10.5.
	This
agreement shall be terminated by the non infringing party pursuant to Article 1456 of the civil code in the event of non compliance of the other party with the essential
agreements referred to articles 2.3, 2.4, 3.3, 3.4, 3.5, 3.6, 3.7, 4.2, 10.4, 16. 

6

  

ARTICLE 11—CONSEQUENCES OF TERMINATION  

        In the event of termination of this Agreement according to Article 10 and the following Article 16, CRINOS shall stop using and: 

	1)
	at
GENTIUM's request, return to GENTIUM all confidential or proprietary information and material supplied by GENTIUM to CRINOS pursuant to this Agreement;

	2)
	at
GENTIUM's option, either:

	(i)
	cancel
the Registration;

	(ii)
	assign
the Registration to GENTIUM or GENTIUM's designee;

	3)
	not
use any of the Trademark, or any trade name, trade dress, service marks or devices applied to or used in association with the Product except for the purposes of selling its
remaining inventory of the Product.

	4)
	not
to use the Patent in any way.

	5)
	both
parties shall continue to be bound by the provisions of Article 6 above for a period of five (5) years after termination of this Agreement. 

ARTICLE 12—NOTICES  

        All notices shall be in writing addressed to the parties at the addresses set forth above. Notices shall be effective when delivered personally or sent by telex,
TWX, facsimile or other telegraphic mode or when sent by registered or certified mail, postage prepaid, so addressed. By notice a party may change its address for future communications. 

ARTICLE 13—WAIVER  

        No failure on the part of either party to exercise, and no delay in exercising any right or remedy shall operate as a waiver of such right or remedy, nor shall
any single or partial exercise of any right or remedy preclude any further or other exercise of such right or remedy. All rights and remedies under this Agreement are cumulative and shall not be
deemed exclusive of any other rights or remedies provided by law. 

ARTICLE 14—FORCE MAJEURE  

	14.1.
	Failure
of either party to perform its obligations under this Agreement (excepting the obligation to make payments) shall not subject such party to any liability to the other if
such failure is caused or occasioned by act of God, or the public enemy, fire, explosion, flood, drought, war, riot, sabotage, embargo, strikes, or other labour trouble, interruption of or delay in
transportation, compliance with any order, regulation or request of any government of competent jurisdiction or any officer, department, agency or committee thereof, including requisition or
allocation or establishment of priority, or by compliance with a request authorised by such governmental authority of any manufacturer for material to be used by it, or by any other event or
circumstance of like or different character to the foregoing beyond the reasonable control of the party so failing.

	14.2.
	The
party suffering an event of force majeure shall immediately notify the other party and both parties shall co-operate in good faith in order to minimise the damages
for both parties. 

ARTICLE 15- DISPUTE RESOLUTION  

        Any disputes between the parties relating to, arising out of or in any way connected with this Agreement, with any term or condition hereof, with the performance
by either party of its obligations 

7

 

hereunder,
whether before or after termination of this Agreement, shall be exclusively submitted to the Court of Milan. 

ARTICLE 16—PROHIBITION OF ASSIGNMENT and SUBLICENSE  

	16.1
	Each
of the party shall not assign this agreement to third not Affiliated companies without the prior written consent of the other party.

	16.2
	CRINOS
shall not sublicense the Patent or dispose in any way of it without the prior written consent of GENTIUM. 

ARTICLE 17—DUTY OF DISCLOSURE  

        CRINOS undertakes to inform GENTIUM within 10 days of any change in the ownership of the company. 

ARTICLE 18—SEVERABILITY  

        If any Article or part thereof contained in this Agreement is declared invalid by any court of competent jurisdiction or a government agency having jurisdiction,
such declaration shall not affect the remainder of the Article or the other Articles and each shall remain in full force and effect. 

ARTICLE 19—GOVERNING LAW  

        The laws of Italy shall govern the interpretation, performance and enforcement of this Agreement. 

ARTICLE 20—ENGLISH LANGUAGE  

        The English language version of this Agreement shall be controlling notwithstanding any translation of the Agreement made for any purpose. 

ARTICLE 21—REGISTRATION TAX.  

        The parties acknowledge that this Agreement is subject to value added tax and consequently is eligible for registration tax only in case of use and at a fixed
rate, pursuant to article 5 and 40 of Presidential Decree No. 131, dated April 26, 1986. 

        IN WITNESS WHEREOF each of the parties has by their duly authorised representatives executed this Agreement as of the date written below. 

	GENTIUM S.p.A	 	CRINOS S.p.A.
	
/s/  DOTT.SSA LAURA IRIS FERRO      
 Name: Dott.ssa Laura Iris Ferro

President and Managing Director	
 	

/s/  DOTT. ENRIQUE HAUSERMANN      
 Name: Dott. Enrique Hausermann

Managing Director
	

15/7/04	
 	

15/07/04
	
 Date	 	
 Date

8

 

        The
following clauses are expressly accepted pursuant to Articles 1341 and following of the civil code: 2.1, 2.2, 2.3, 3.3, 3.4, 3.5, 4.2, 11, 15, 10.2, 10.3, 10.4, 16, 19. 

	GENTIUM S.p.A	 	CRINOS S.p.A.
	
/s/  DOTT.SSA LAURA IRIS FERRO      
 Name: Dott.ssa Laura Iris Ferro

President and Managing Director	
 	

/s/  DOTT. ENRIQUE HAUSERMANN      
 Name: Dott. Enrique Hausermann

Managing Director
	

15/7/04	
 	

15/07/04
	
 Date	 	
 Date

9

 
 
 

GENTIUM- CRINOS    
    
    LICENSE AGREEMENT    
    
    EXHIBIT A    
    

PATENT  

        Procedimento per l'ottenimento di polidesossiribonucleotidi clinicamente definiti e riproducibili e prodotto farmacologicamente attivo
risultante.

	Reg. No.
	 	Filed on

	IP 11903131	 	17.04.1986

10

 
 
 

GENTIUM- CRINOS    
    
    LICENSE AGREEMENT    
    
    EXHIBIT B    
    

PRODUCTS  

        AIC Number 02608052 21 capsules 400mg 

        AIC
Number 026086025 10 ampoules 2,5ml 200mg 

11

QuickLinks

Exhibit 10.17

LICENCE AGREEMENT

GENTIUM- CRINOS LICENSE AGREEMENT EXHIBIT A

GENTIUM- CRINOS LICENSE AGREEMENT EXHIBIT BQuickLinks
 -- Click here to rapidly navigate through this document

 
 

Exhibit 10.18    
    

        EXECUTION COPY 

 
 

PURCHASE AGREEMENT    
    
    BY AND BETWEEN    
    
    SIRTON PHARMACEUTICALS S.p.A.    
    
    AND    
    
    GENTIUM S.p.A    
    
    AND    
    
    AXCAN PHARMA INC.
  
    
  
  
  October 9, 2002    
    

 
 

TABLE OF CONTENTS    
    

	 
	 	 
	 	 
	 	Page

	1.	 	INTERPRETATION	 	3
	 	 	1.1	 	Definition	 	2
	 	 	1.2	 	Schedules	 	3
	 	 	1.3	 	Currency	 	4
	 	 	1.4	 	Choice of Law and Attornment	 	4
	

2.	
 	

SALE AND ASSIGNMENT	
 	

4
	 	 	2.1	 	Purchased Patent, Technology	 	4
	 	 	2.2	 	Technology Transfer, Support and Regulatory Approvals	 	4
	 	 	2.3	 	Report on Patent Applications	 	5
	3.	 	TRANSFER OF OWNERSHIP	 	5
	4.	 	PURCHASE PRICE	 	5
	 	 	4.1	 	Payments	 	5
	 	 	4.2	 	Reporting	 	5
	5.	 	CLINICAL TRIALS	 	6
	6.	 	FIRST RIGHT OF REFUSAL	 	6
	7.	 	UNDERTAKINGS OF THE VENDORS	 	7
	 	 	7.1	 	Clinical Supplies	 	7
	 	 	7.2	 	Commercial Supply (dispensing mechanism)	 	7
	8.	 	REPRESENTATIONS AND WARRANTIES	 	7
	 	 	8.1	 	Representations and Warranties of the Vendors	 	7
	9.	 	SURVIVAL OF WARRANTIES AND INDEMNIFICATION	 	9
	 	 	9.1	 	Survival of Warranties	 	9
	 	 	9.2	 	Vendors' Liability for Damages and Indemnification	 	9
	 	 	9.3	 	No Indemnification	 	9
	10.	 	CONFIDENTIALITY	 	10
	 	 	10.1	 	Confidential Information	 	10
	 	 	10.2	 	Non-Competition	 	10
	11.	 	FURTHER ASSURANCES	 	10
	12.	 	GENERAL	 	11
	 	 	12.1	 	Successors and Assigns	 	11
	 	 	12.2	 	Force Majeure	 	11
	 	 	12.3	 	No Agency	 	11
	 	 	12.4	 	Entire Agreement	 	11
	 	 	12.5	 	Severability of Clauses	 	11
	 	 	12.6	 	Waiver	 	11
	 	 	12.7	 	Notices	 	12
	 	 	12.8	 	Execution in Counterparts	 	12
	 	 	12.9	 	Headings	 	12
	 	 	12.10	 	Compliance with Laws	 	12
	 	 	12.11	 	Taxation	 	13
	 	 	12.12	 	Assignment	 	13
	 	 	12.13	 	Arbitration	 	13

*
* * 

 
 

EXECUTION COPY    
    

 
 

PURCHASE AGREEMENT    
    

THIS AGREEMENT is made and entered into this 9th day of October, 2002. 

	 
	 

	BY AND BETWEEN:	 
	

 	
SIRTON PHARMACEUTICALS S.p.A. (formerly known as CRINOS INDUSTRIA FARMACOBIOLOGICA S.p.A), a corporation duly constituted under the laws of Italy having its principal place of business at
Piazza XX Settembre n. 2, 22079 Villa Guardia (Como), Italy;
	

 	

(hereinafter referred to as "Vendor 1")
	
AND:	

 
	

 	
GENTIUM S.p.A., a corporation duly constituted under the laws of Italy having its principal place of business at Piazza XX Settembre n. 2, 22079 Villa Guardia (Como), Italy;
	

 	

(hereinafter referred to as "Vendor 2"))
	

 	

(Vendor 1 and Vendor 2 hereinafter collectively referred to as the "Vendors")
	
AND:	

 
	

 	
AXCAN PHARMA INC., a corporation duly constituted under the Canada Business Corporations Act having its principal place of business at 597
Laurier Blvd, Mont St. Hilaire, Quebec, Canada J3H 6C4, or its designee.
	

 	

(hereinafter referred to as: the "Purchaser")

 
 

PREAMBLE

WHEREAS Vendor 2 is the owner of patents for a stable aqueous formulation of mesalazine which Vendor 1 currently manufactures and which is sold in the
territories of Italy, San Marino and Città del Vaticano as a gel dispensing canister dosage form under the trade-mark "Enterasin" and "Quota" respectively by the semi
exclusive licensees Crinos S.p.A. and Abbott S.p.A., which are also the owners of the relative trademarks; 

WHEREAS the Vendors own and hold know-how related to the formulation, packaging and manufacture of this product. 

WHEREAS Vendor 1 has entered into an agreement in order to obtain Commercial Advantages (as hereinafter defined) for a supply of and use of the patented
gel dispensing valve and sachet mechanism it currently uses in the canisters, with it's patent holder EP Spray Systems SA ("EP Spray Systems"). 

WHEREAS the Vendors have agreed to (i) sell to the Purchaser all of the Vendors' rights, title and interest in and to those of the Vendors'
patents related to the product which are issued or pending in the United-States, and (ii) grant the Purchaser a right of first refusal to purchase rights in and to patents and other rights
related to the product, including know-how, in other territories outside Europe. 

 

WHEREAS the Vendors have agreed to transfer and assign to the Purchaser know-how related to the product and the benefit of the Commercial
Advantages they hold to a supply and use of the gel dispensing valve and sachet mechanism. 

NOW, THEREFORE, in consideration of the above premises and covenants and agreements herein contained, the Preamble forming an integral part of the
present Agreement, the parties hereto agree as follows: 

1.     INTERPRETATION

	1.1
	Definition

The
following terms used in this Agreement shall have the following meanings: 

	1.1.1
	"Affiliate" shall mean, with respect to any Person (as hereinafter defined), any other Person that at such time directly, or
indirectly through one or more intermediaries, controls or is controlled by or under common control with, such Person. As used in this definition,  "control" means the possession as beneficial owner of
fifty percent plus one (50% plus 1) of the voting rights of a Person;

	1.1.2
	"Commercial Advantages" means the "avantage concurrentiel" granted to the Vendors by EP Spray Systems SA, a Swiss company, to obtain
exclusive supplies of and use of its patented valve and sachet mechanism in accordance with the letter dated December 21, 1995 addressed to Vendors by EP Spray Systems SA and the letter dated
January 10, 2001, both of which are attached herewith as Schedule 1.1.2;

	1.1.3
	"Effective Date" means the date first written above;

	1.1.4
	"European Countries" means any one or a number of the countries listed in Schedule 1.1.4, as the case may be;

	1.1.5
	"Gel" means a compound covered by the Invention which is further defined in Schedule 1.1.5;

	1.1.6
	"Intellectual Property" shall mean any intellectual property rights including without limitation any rights under any patent, trade
secret, copyright or know-how;

	1.1.7
	"Invention" shall mean the invention entitled "Stable Aqueous Suspension of Mesalazine", being the subject of the Patents, as such
title may be amended from time to time;

	1.1.8
	"Liabilities" shall mean losses, damages, fines, costs, liabilities and expenses (including the reasonable fees, costs and expenses
of attorneys and other professional and court costs), based on any civil, criminal, statutory or regulatory claims of liability;

	1.1.9
	"NDA" means new drug applications pursuant to the United States Food, Drugs and Cosmetics
Act;

	1.1.10
	"Net Sales" shall mean the gross receipts by Axcan from a third party attributable to Axcan's sale of the Product, less the
following amounts:

	1.1.10.1
	discounts,
in amounts customary in the trade, for quantity purchases, cash payments, prompt payments, wholesalers, and distributors;

	1.1.10.2
	development
discounts to specific academic or other charitable or public groups or institutions;

	1.1.10.3
	credits
or refunds for claims or returns;

	1.1.10.4
	prepaid
outbound transportation expenses;

	1.1.10.5
	prepaid
transportation insurance premiums; 

2

 

	1.1.10.6
	uncollectable
accounts receivable; and

	1.1.10.7
	taxes;
including sales, value-added, use, turnover, excise, import, export, and other taxes or duties, imposed by government or a government agency on such use, sales, or
transfer of the Product.

	1.1.11
	"Other Patents" shall mean any patents issued or patent applications filed in any jurisdiction in the world outside the Territory
related to the Invention, the Purchased Patent or the Gel including any patent applications or patents deriving therefrom and any corresponding patent applications and patents issued therefrom;

	1.1.12
	"Patents" shall mean all patents and patent applications related to the Gel and the Invention, as listed in Schedule 1.1.12
hereto.

	1.1.13
	"Purchased Patent" shall mean the Patents issued and patent applications filed in the Territory listed in Schedule 1.1.13,
and any patent applications and patents deriving therefrom;

	1.1.14
	"Person(s)" shall mean an individual, partnership, corporation, business, trust, joint venture or other entity of a similar nature;

	1.1.15
	"Product(s)" shall mean a gel dispensing canister dosage form containing as an active ingredient, the mesalazine (mesalamine)
formulation embodied in the Purchased Patent;

	1.1.16
	"Technology" shall mean all technology, intellectual and industrial property, including without limitation the know-how,
inventions, improvements, formulae, and trade secrets necessary or useful to exploit the Patents and the Invention and to formulate, manufacture and package the Gel and the Product;

	1.1.17
	"Territory" shall mean the geographical boundaries of the countries known, on the Effective Date, as Canada and United States of
America and any other country agreed upon by the parties from time to time;

	1.1.18
	"Third party" shall mean any Person (a) not a party to this Agreement; or (b) not an Affiliate of a party to this
Agreement;

 

	1.2
	Schedules

The
schedules, which are attached to this Agreement, are incorporated into this Agreement by reference and are deemed to be part hereof 

	Schedule
 
	 	Description
 

	

1.1.2	
 	

Commercial Advantages
	

1.1.4	
 	

European Countries
	

1.1.5	
 	

Gel Formulation
	

1.1.12	
 	

Patents
	

1.1.13	
 	

Purchased Patent
	

2.3	
 	

Status Reports on Patent Applications
	

7.2	
 	

Terms of Supply
	

11	
 	

Assignment Agreement

3

  

	1.3
	Currency

Unless
otherwise indicated, all amounts referred to in this Agreement are in lawful money of the European Economic Community ("Euro"). 

1.4   Choice of Law and Attornment  

        This Agreement shall be governed by and construed in accordance with the laws of the province of Quebec and the laws of Canada applicable therein without regard
to conflict of law principles. 

2.     SALE AND ASSIGNMENT  

2.1   Purchased Patent, Technology  

	2.1.1
	Purchased
Patent 

        On
the terms and conditions of this Agreement, the Vendors hereby irrevocably sell and assign to the Purchaser all of the Vendors' rights, title and interest in and to the Purchased
Patent. 

	2.1.2
	Technology

        On
the terms and conditions of this Agreement, the Vendors hereby irrevocably sell and assign to the Purchaser all of the Vendors' rights, title and interest in and to the Technology for
the Territory. 

        Without
limiting the generality of the foregoing, the Purchaser shall have an unlimited, exclusive right to use the Technology to develop, formulate, make, have made, use, sell, have
sold and offer for sale, the Gel and the Product in the Territory. 

	2.1.3
	Commercial
Advantages 

        On
the terms and conditions of this Agreement, the Vendors hereby undertake to transfer the benefit of the Commercial Advantages to the Purchaser, effective upon receipt of the consent
of EP Spray Systems SA pursuant to Section 7.2. 

2.2   Technology Transfer, Support and Regulatory Approvals  

	2.2.1
	Effective
Transfer of Information 

        On
the Effective Date, the Vendors undertake to provide the Purchaser with all the information regarding the Purchased Patent and the Technology in whatever form or medium whether in
oral, written, graphic or electronic form, including without limitation manuals and standard operating procedures for the formulation, manufacture, packaging and labelling of the Product, and agree on
a continuing basis to forward to the Purchaser any such information and documentation that the Vendors may develop or acquire. 

	2.2.2
	Support
and Training 

        On
and after the Effective Date, on a continuing basis, the Vendors shall provide the Purchaser with transitional support, training and expert advice, without payment of any additional
consideration by the Purchaser, for so long as it may be necessary to ensure an effective transfer to the Purchaser, its officers, agents and employees of all the Technology, know-how and
other technical information necessary or useful to exploit the Patents and the Invention and to formulate, manufacture and package the Gel and the Product. Without limiting the generality of the
foregoing, the Vendors shall, upon the request of the Purchaser, make available their (i) qualified personnel whether at their premises or at the premises of the Purchaser, at the Purchaser's
discretion and (ii) manufacturing facilities. The Purchaser shall bear the cost of reasonable travelling expenses incurred by the Vendors' employees in connection with the Vendors' obligations
hereunder. 

4

 

	2.2.3
	Regulatory
Approvals 

        The
Vendors shall co-operate and assist the Purchaser in obtaining all permits, licenses, authorisations, registrations or approvals issued or to be issued by any federal,
provincial, state, municipal, local or foreign government or governmental agency, board, commission or other authority as may be necessary or useful for the formulation, manufacture, packaging, sale,
distribution, marketing or promotion of the Product (the "Regulatory Approvals"). In assisting the Purchaser to obtain the Regulatory Approvals, and in order to fulfil its obligations pursuant to the
present Section 2.2.3, the Vendors shall disclose to the Purchaser and provide the Purchaser with a copy of their regulatory dossier including without limitation all results of clinical
research and trials, analytical test methods and validations thereof, drug master files and other data arising from any studies that may have been or may be performed in relation to the Product, the
Patents, the Invention and the Technology. 

2.3   Report on Patent Applications  

        The Vendors shall provide to the Purchaser, on the Effective Date, an up-to-date report on the status of each of the patent applications
comprised in the Purchased Patent, and an up-to-date report on the status of each of the patent applications filed outside the Territory, such reports to be attached herewith
as Schedule 2.3. 

3.     TRANSFER OF OWNERSHIP  

        Notwithstanding anything else contained in this Agreement, ownership of the Purchased Patent and the Vendors' rights in and to the Technology for the Territory,
shall be transferred to the Purchaser on the Effective Date. 

4.     PURCHASE PRICE  

4.1   Payments  

        The aggregate purchase price for the Purchased Patent and the Vendors' rights in and to the Technology for the Territory and the Commercial Advantages, which
includes all applicable taxes, shall be payable as follows: 

	(a)
	one
hundred and eighty-seven thousand five hundred Euro (€ 187,500) upon the execution of this Agreement;

	(b)
	three
hundred and seventy five thousand Euro (€ 375,000) within sixty (60) days of the filing of an NDA for the Product in the United States by the
Purchaser;

	(c)
	nine
hundred and thirty seven thousand five hundred Euro (€ 937,500) within sixty (60) days of receipt by the Purchaser of the marketing approval
for the Product in the United States of America;

	(d)
	a
deferred price of four percent (4%) of the Net Sales of the Product in the Territory for a period of ten (10) years beginning on the date of first commercialisation of the
Product within the Territory provided however that the Vendors' right to such deferred price in a given country or countries shall immediately terminate in the event that the Purchased Patent is
invalidated or determined to be unenforceable for any reason in such country or countries. 

4.2   Reporting  

        The Purchaser shall provide yearly, before the end of January, to Vendors, certified statements regarding the Net Sales amount of the former calendar year. Not
more than once a year, and at the Vendors' expense, upon at least fifteen (15) days notice and during normal business hours, the Vendors' 

5

 

duly
authorized certified public accountant shall be permitted to inspect such books and records which contain the data relevant to the computation of the deferred price referred to in
paragraph (d) of Section 4.1. The Purchaser may require that the certified public accountant execute and deliver a non-disclosure agreement promising not to disclose such Confidential
Information of the Purchaser other than to the Vendors for the purposes mentioned in the present Section 4.2. 

5.     CLINICAL TRIALS  

        The Purchaser shall use commercially reasonable efforts to pursue the clinical trials for the Product in an effort to file an NDA for the Product in a timely
manner. In the event that the Purchaser has not obtained the approval for the NDA for the Product by December of the year 2005, the Purchaser shall, upon the request of Vendor 2, grant Vendor 2 a
non-exclusive, non-transferable, royalty-bearing licence to use the Purchased Patent, with the possibility for Vendor 2 to sublicense, at the same terms and conditions
described in paragraph (d) of Section 4.1, provided however that the delay in obtaining the NDA is in no way due to (i) the fault or negligence of any of the Vendors or any of the
Vendors' failure or negligence to fulfil their obligations under this Agreement, (ii) reasons that are out of the Purchaser's control or (iii) the failure to receive sufficient supply of
Product required to pursue the appropriate studies. 

6.     FIRST RIGHT OF REFUSAL  

	6.1.1
	With
the only exception of European Countries, where a first right of refusal for an exclusive or semi-exclusive license for registration, promotion, sale and
commercialisation of all existing and future indications of the active ingredients Mesalazina has been granted to Crinos S.p.A., if at any time either of the Vendors intends to accept an offer from a
third party to purchase, licence or otherwise obtain rights to exploit, register, promote or commercialise the Products or any existing or future indications of the active ingredients Mesalazina
outside the Territory, including by the purchase, license or other right to exploit, use or otherwise commercialise or transact in any manner the Other Patents, the Commercial Advantages or the
Technology outside the Territory (the "Third Party Offer"), the Vendors shall immediately send a written notice to the Purchaser (the "Notice") offering to sell or licence the same rights to the
Purchaser at the same price and in all other respects upon the same terms and conditions as provided in the Third Party Offer. The Vendors shall deliver to the Purchaser a true copy of the Third Party
Offer with the Notice. The offer contained in the Notice shall be irrevocable except with the consent of the Purchaser and shall be open for acceptance by the Purchaser for a period of ninety
(90) days after the date upon which the Notice was received by the Purchaser (the "Acceptance Period");

	6.1.2
	Upon
the Notice being given, the Purchaser shall have the right to accept the offer contained in the Notice by giving the Vendor a notice in writing to that effect at any time
during the Acceptance Period. If the Purchaser accepts the offer contained in the Notice, the transaction between the Purchaser and the Vendor shall be completed within sixty (60) days of the
expiry of the Acceptance Period. If the Purchaser refuses the offer contained in the Notice, the Vendor shall have the right to accept the Third Party Offer, and the transaction between the Vendor and
such third party shall be completed within sixty (60) days following the expiry of the Acceptance Period and upon the same terms and conditions as the Third Party Offer failing which the
provisions of this Section 6 shall again apply to any proposed transaction with a third party and so on from time to time.

	6.1.3
	Without
limiting the generality of the foregoing, in the event that the Purchaser obtains any right to the Other Patents, the Technology or the Products in any country or countries
outside the Territory, the Vendors hereby undertake to automatically transfer to the Purchaser the benefit of the Commercial Advantages in such country or countries. 

6

 

7.     UNDERTAKINGS OF THE VENDORS  

7.1   Clinical Supplies  

        The Vendors hereby undertake to deliver to the Purchaser such quantities of finished Product it from time to time requires in order to carry-out
clinical studies required in order to pursue regulatory approvals for the Product. The Purchaser will issue purchase orders for the required quantities and the price and terms of delivery of these
supplies shall be no less favourable than those offered to the Vendors' preferred customers. Clinical supplies will be manufactured according to GMP standards, the Purchaser acknowledging that the
Vendors' manufacturing facility is not FDA certified. 

7.2   Commercial Supply (dispensing mechanism)  

	7.2.1
	Upon
the Purchaser's request, the Vendors hereby undertake to seek the consent of EP Spray Systems SA for the transfer and assignment of the Commercial Advantages to the Purchaser
and to assist the Purchaser in securing a supply agreement with EP Spray Systems SA on terms no less favourable than those offered to the Vendors and indicated in Schedule 7.2. In the event
such consent and supply cannot be obtained upon such terms or such other commercially reasonable terms acceptable to the Purchaser, the parties will collaborate in securing alternative sources of gel
dispensing mechanisms or, at Purchasers' option, the Vendors will supply the Purchaser with its requirements for gel dispensing mechanisms purchased from EP Spray Systems SA.

	7.2.2
	The
Vendors shall immediately notify the Purchaser of any intended changes to the terms of their supply agreement with EP Spray Systems SA and if changes to such terms are actually
agreed upon between the Vendors and EP Spray Systems SA, the Vendors shall immediately notify the Purchaser of the agreed changes and Schedule 7.2 shall be amended for the sole purpose of
reflecting such changes in Schedule 7.2.

	7.2.3
	In
the event that either of the Vendors supplies the Purchaser, a supply agreement will be entered. Price and terms of sale will be no less favourable than those offered to Vendors
by EP Spray Systems SA. The Purchaser acknowledges that reasonable shipping and handling expenses for the supply will be at its expense provided however that it has approved the shipping and handling. 

8.     REPRESENTATIONS AND WARRANTIES  

8.1   Representations and Warranties of the Vendors  

        The
Vendors hereby represent and warrant to the Purchaser as follows and hereby acknowledge and confirm that the Purchaser is relying on these representations and warranties in
connection with the purchase by it of the Purchased Patent and the Technology: 

	8.1.1
	Authority    They have full power and authority to enter into and perform their obligations pursuant to this Agreement and
to consummate the transactions contemplated herein.

	8.1.2
	Binding Obligation    The execution, delivery and performance of this Agreement has been duly authorised by all necessary
corporate action and constitutes a legal, valid and binding obligation of the Vendors, subject to applicable bankruptcy, reorganisation, insolvency, moratorium and similar laws affecting creditors'
rights generally.

	8.1.3
	No Contravention    The execution, delivery and performance of this Agreement does not conflict with or contravene any
provision of the Vendors' charter documents or by-laws nor will it conflict with or result in a breach of, default under or creation of a lien, charge or encumbrance upon the Vendors'
assets, pursuant to the terms, conditions or provisions of any 

7

 

agreement,
instrument, mortgage, indenture or contract to which they are a party or by which they or their properties are bound. Neither the execution nor the delivery or performance of this Agreement
by the Vendors shall contravene any provision of the laws of any applicable jurisdiction, including, without limitation, any statute, rule, regulation, judgement, decree, order, decision, franchise or
permit applicable to them. 

	8.1.4
	No Consent of Third Parties Needed    No consent of any trustee or holder of any of its indebtedness or any other Person is
or shall be required as a condition to the validity of this Agreement.

	8.1.5
	No Proceedings Pending    There is no action or proceeding pending or, in so far as it knows, threatened against it before
any court, administrative agency or other tribunal which might have an adverse effect on the Patents, the Invention, the Technology, the Commercial Advantages or the Vendors' ability to perform their
obligations hereunder.

	8.1.6
	No Brokers    No party has taken any action or has entered into any agreement, understanding or other arrangement that
would obligate the other party to pay any broker's or finder's fee or any commission or similar fee to any agent, broker, investment banker or other Person in connection with any of the transactions
contemplated by this Agreement.

	8.1.7
	Ownership    Vendor 2 owns the Patents and the Invention free and clear of any and all encumbrances. Vendor 1
owns the Technology free and clear of any and all encumbrances and the Vendors possess the rights to the Commercial Advantages free and clear of any and all encumbrances. Vendor 1 and
Vendor 2 are entitled to assign all of their respective rights, title and interest in and to the Purchased Patent, the Invention and the Technology, to the Purchaser.

	8.1.8
	No Restrictions    There are no restrictions on the ability of the Vendors or any successor to or assignee from the Vendors
to use or exploit all of their respective rights in the Patents, the Invention, the Technology and the Commercial Advantages. No royalty or other fee is required to be paid by either of the Vendors to
any other Person in respect of the use or commercialisation of the Patents, the Invention the Technology or the Commercial Advantages. Neither of the Vendors have granted any license or other rights
on the Patents, the Invention or the Technology for the Territory to any Person. Neither of the Vendors have granted any rights to the Commercial Advantages to any Person. The Vendors have the
exclusive right to use all of the Patents, the Invention, the Technology and the Commercial Advantages and have not granted any licence, options to purchase or other rights to any other Person in
respect thereof except for (i) the rights granted to Crinos S.p.A and Abbott S.p.A in the territories of Italy, San Marino and Città del Vaticano, (ii) the first right of
refusal granted to Crinos S.p.A in the European Countries.

	8.1.9
	Patents    The rights in the Patents and the Technology are sufficient for the Purchaser to develop, produce, formulate,
manufacture, have manufactured, package, market, use, sell, offer for sale, import, export and distribute the Gel and possess the Patents undisturbed. The list of patents found in
Schedule 1.1.13 constitutes a complete and exhaustive list of all the patents issued and patent applications filed in the Territory, for the Invention and for the development, formulation and
manufacture of the Gel, including any divisions, patents of addition, reissues, reexaminations, or extensions of any of the foregoing, including any continuations or
continuations-in-part and any patents or patent applications otherwise derived therefrom. The Patents have been properly filed, are validly subsisting and all maintenance fees
and similar annuity payments have been made in each of the jurisdictions requiring such payments. All the true inventors were rightly named in the applications for the registration of the Patents and
all statements contained in such applications were true and correct as of the date of such applications. All assignments have been obtained by the Vendor 2 and are valid 

8

 

and
sufficient to vest all rights, title and interest in the Patents and the Invention with Vendor 2. 

	8.1.10
	Infringement    The Vendors acknowledge that prior to the execution of this Agreement, they have made reasonable
investigations concerning the validity of the Patents and their non infringement of other Persons' rights. To the best of Vendors' knowledge, the results of said investigations are accurate and the
use of the Patents, the Invention and the Technology does not infringe, and the Vendors are not a party to any pending suit and have not received any notice, complaint, threat or claim alleging
infringement of, any Intellectual Property right or propriety right of any other Person, and does not include any activity which may constitute passing off.

	8.1.11
	Disclosure    The Vendors have fully provided the Purchaser with all of the information necessary or useful for deciding
whether to purchase the Purchased Patent and the Technology and have not omitted to provide any information which may have a material adverse effect on the Patents, the Technology or the transactions
contemplated herein or information which if known to the Purchaser may have caused the Purchaser to not enter into this agreement. 

9.     SURVIVAL OF WARRANTIES AND INDEMNIFICATION  

9.1   Survival of Warranties  

        The representations and warranties made by the Vendors contained in this Agreement, or contained in any document or certificate given in order to carry out the
transactions contemplated by this Agreement, will survive the execution of the transactions contemplated by this Agreement and, notwithstanding any investigation made by or on behalf of the Purchaser
or any other Person or any knowledge of the Purchaser or any other Person, shall continue in full force and effect for the benefit of the Purchaser. 

9.2   Vendors' Liability for Damages and Indemnification  

        The Vendors (and their Affiliates) will be liable for and agree, at their own expense, to defend, indemnify, protect and hold harmless the Purchaser and its
Affiliates and their respective officers, directors, employees, representatives and agents from and against any and all Liabilities (including costs and attorney's fees), asserted at any time, arising
out of or involving (i) any misrepresentation or inaccuracy in any representation or warranty given by the Vendors in this Agreement or in any other document delivered pursuant hereto by the
Vendors or (ii) any breach or non-performance by the Vendors of any covenant to be performed by either of them under this Agreement or in any other document delivered pursuant
hereto by the Vendors. 

9.3   No Indemnification  

        The Vendors shall not ask for any reimbursement of expenses or file any claim for damages against the Purchaser or its Affiliates and neither the Purchaser nor
any of its Affiliates shall be liable for any damages, claims, demands, actions, causes of action, costs, expenses or other losses in any way suffered by the Vendors related to the omission or failure
of the Purchaser to file the NDA for the Product, to obtain approval from the NDA or otherwise related to this Agreement. The Vendors acknowledge that their only remedy in such a situation shall be
the right to request a non-exclusive licence from the Purchaser in accordance with Article 5 provided however that in the case where the Purchaser omits or fails to file the NDA for
the Product, the non-exclusive licence from the Purchaser shall be royalty-free. 

9

 

10.   CONFIDENTIALITY  

10.1 Confidential Information  

        "Confidential Information" means all confidential information related to the business of the disclosing party that may be obtained by the receiving party from any
source as a result of this Agreement. Confidential Information includes (but is not limited to) concepts, pricing information, business methods, business and technical plans, inventions, research,
tests and clinical studies and know-how. 

        The
parties shall not, at any time or under any circumstances, without the prior written consent of the other party, directly or indirectly communicate or disclose to any Person any
confidential knowledge or information of the other party nor shall it utilise or make available any such knowledge or information directly or indirectly in connection with any business or activity in
which it is or proposes to be involved except as required to give effect to this Agreement without the consent of the other party. The parties shall take appropriate measures to ensure that the
Confidential Information remains secret. For the purposes of this section, shall be excluded from the obligations of non-disclosure hereunder the confidential information which a party
demonstrates was a part of the public domain prior to the execution of the present Agreement, through no act or omission of the other party, its officers, employees, agents, advisor or other
representatives. 

10.2 Non-Competition  

        The Vendors in selling the Purchased Patent and the Technology as provided herein, may no longer use or otherwise exploit the Purchased Patent or the Technology
in the Territory. The Vendors shall ensure that neither the Vendors nor any of their Affiliates, unless authorised by the Purchaser, will for the period of the validity of the Patents and for a period
of two (2) years thereafter, directly or indirectly, either alone, through their subsidiaries, Affiliates, directors, officers or any other Person, by contract or otherwise, or in partnership
or in conjunction with any other Person or Persons, whether as principal, agent, shareholder or independent contractor or otherwise, carry on or be engaged in, or advise with respect to the
development, manufacture, distribution, sale, marketing, or promotion of any product which competes with the Product in the Territory whether patents subsist or not in each such jurisdiction. The
Vendors undertake to use commercially reasonable efforts to include in any agreements entered into with third parties, after the date of execution of this Agreement, related to the Patents or the
Technology, a provision requiring that the third parties refrain from promoting, selling or otherwise transacting, directly or indirectly, any product which competes with the Product in the Territory
for the duration of the agreement with the third party. 

        The
Vendors hereby agree that they shall under no circumstances transfer the benefit of or otherwise transact the Commercial Advantages related to the Territory to or with any Person
other than the Purchaser. 

11.   FURTHER ASSURANCES  

        The Vendors shall co-operate with the Purchaser, and execute and deliver, or cause to be executed and delivered, all such other instruments, documents
or agreements including without limitation an instrument of assignment of the Purchased Patent substantially in the form of the assignment attached herewith as Schedule 11, and take all such
other actions as the Vendors may be requested to take by the Purchaser from time to time in order to implement the provisions and purposes of this Agreement. 

        Without
limiting the generality of the foregoing, the Vendors hereby undertake to execute, deliver and/or file, at their expense, immediately upon the execution of the present Agreement,
but in any event by no later than within ten (10) days of the execution of the present Agreement, all instruments, documents or agreements necessary or useful to vest all the rights, title and
interest in and to the 

10

 

Purchased
Patent in the Purchaser, including without limitation, such instruments, documents or agreements necessary or useful to (i) record the change of name of Vendor 1 from Crinos Industria
Farmacobiologica S.p.A to Sirton Pharmaceuticals S.p.A with the appropriate patent offices, if necessary (ii) ensure that the assignment of the Purchased Patent from Vendor 1 to Vendor 2 has
been properly filed for registration with the appropriate patent offices and (iii) the Vendors shall do all such other acts that may be necessary or useful to vest all rights, title and
interest in and to the Purchased Patent in the Purchaser and to ensure that the Purchaser is recorded as the registered owner of the Purchased Patent in the appropriate patent offices, in whatever
order as may be required. 

12.   GENERAL  

12.1 Successors and Assigns  

        The terms and provisions of this Agreement shall inure to the benefit of, and be binding upon, the Purchaser and the Vendors and their respective successors and
permitted assigns. 

12.2 Force Majeure  

        Neither party shall be liable for delays in performance under this Agreement occasioned by force majeure or any cause beyond its control, including but not
limited to war, civil disturbance, fire, flood, earthquake, windstorm, acts of default of common carriers, strikes, unforeseen shutdowns of sources of supply, governmental laws, acts, regulations or
orders (whether or not such later prove to be invalid) or any other occurrence, whether or not similar in character to the foregoing. 

12.3 No Agency  

        The Purchaser and the Vendors are independent contractors. Neither is the agent or legal representative, joint venturer, partner, employee or employer of the
other. The Purchaser agrees not to represent itself as the agent or legal representative of the Vendors and the Vendors agree not to represent themselves as the agent or legal representative of the
Purchaser. This Agreement does not grant any party any authority to assume or create any obligation on behalf of or in the name of the other party. 

12.4 Entire Agreement  

        The terms and conditions of this Agreement supersede the terms and conditions of any and all prior agreements and any and all representations that may have been
made prior to this Agreement with respect to the subject matter of this Agreement. The terms and conditions herein constitute the entire agreement between the parties hereto and may not be amended,
changed, modified, contradicted, explained or supplemented (including by course of dealing between the parties, usage of trade or otherwise) except by a written instrument signed by an authorised
officer of the Purchaser and the Vendors (as the case may be) which refers specifically to this Agreement. 

12.5 Severability of Clauses  

        If any provision of this Agreement is determined to be illegal, against public order, or otherwise unenforceable it shall not in any way defeat, invalidate or
render unenforceable any other provision of this Agreement and each such provision shall at all times be considered separate and severable in this Agreement. 

12.6 Waiver  

        No waiver by either of the parties of any breach of any provision hereof shall constitute a waiver of any other breach of any provision hereof. 

11

  

12.7 Notices  

        Any notice required by this Agreement shall specifically reference this Agreement, shall be in writing and may either be delivered in hand, by facsimile during
normal business hours with confirmation of receipt or by reputable overnight courier service to the addresses set forth below, or such other address for itself as any of the parties may from time to
time specify in writing to the other party in accordance with this article. No notice shall be deemed given until it is actually received. 

	If to Vendor 1:	 	Sirton Pharmaceuticals S.p.A,

Piazza XX Settembre n. 2,

22079 Villa Guardia (Como),

Italy	 	 
	

 	
 	

Attention of:

Facsimile number:	
 	

Dott.ssa Laura Iris Ferro

(031) 481 784
	

If to Vendor 2:	
 	
Gentium S.p.A.

Piazza XX Settembre n. 2,

22079 Villa Guardia (Como),

Italy	
 	

 
	

 	
 	

Attention of:

Facsimile number:	
 	

Dott.ssa Laura Iris Ferro

(031) 481 784
	

If to the Purchaser:	
 	
Axcan Pharma Inc

597 Laurier Blvd,

Mont St. Hilaire,

Quebec, Canada J3H 6C4	
 	

 
	

 	
 	

Attention of:

Facsimile number:	
 	

President

(450) 464-9979
	

 	
 	

With a copy to:	
 	

 
	

 	
 	
Léer Robic Richard

55 St-Jacques

Montreal, Quebec

Canada H2Y 3X2	
 	

 
	

 	
 	

Attention of:

Facsimile number:	
 	

François Painchaud

(514) 845-7874

	12.8
	Execution in Counterparts

This
Agreement may be executed in counterparts, each of which, when so executed and delivered, shall be deemed to be an original, and all of which counterparts, taken together, shall constitute one
and the same instrument. 

	12.9
	Headings

Headings
used herein are for convenience only and shall not in any way affect the construction of or be taken into consideration in the interpretation of this Agreement. 

	12.10
	Compliance with Laws

Each
party hereto shall comply with all applicable statutes, ordinances, rules, regulations, permits and orders imposed by any governmental authority on any activity of any party hereunder. 

12

 
	12.11
	Taxation

All
taxes or other duties imposed on either of the Vendors in the country of residence of the Purchaser on any payment due or made under this Agreement shall be borne by the Vendors. To the extent
that the tax regulations of the country of residence of the Purchaser require the Purchaser to deduct or withhold the above taxes from the payments due under this Agreement to the Vendors, then the
Purchaser shall deduct or withhold the tax and provide the Vendors with receipts from the competent taxation authorities as evidence of the payment of such taxes within forty-five
(45) days of such payment. If such amounts can be reduced or avoided in accordance with the terms of a double taxation treaty between the relevant countries, then the Purchaser shall reasonably
assist the Vendors, at the Vendors' cost, with the appropriate requests in obtaining the certificates as to give effect to obtaining in advance the right to avoid the tax or to deduct the taxes or
charges at the lower rate as specified in said treaty. 

	12.12
	Assignment

None
of the parties hereto may assign this Agreement without the prior written consent of the other parties, provided however that the Purchaser may, without the consent of the other parties, assign,
license or otherwise transfer its rights under this agreement in whole or in part (i) to any of its Affiliates or (ii) to any entity to whom the Purchaser has assigned the whole or any
part of its business related to this agreement. 

	12.13
	Arbitration

Any
dispute, controversy or claim between the Purchaser and either of the Vendors relating to the breach, construction, interpretation, application of (or at the occasion of) this Agreement, shall be
settled, when permitted by law, by binding arbitration under the following terms and conditions: 

	12.13.1
	either
the Purchaser or the Vendors may demand that a dispute, controversy, or claim be submitted to arbitration. Such demand shall be made in writing to the other party at the
notification address set forth in this Agreement;

	12.13.2
	all
matters submitted by the Purchaser or the Vendors for settlement by binding arbitration shall be decided by a single arbitrator agreeable to both the Purchaser and the
Vendors. If the Purchaser and the Vendors are unable to agree upon a single arbitrator within a period of fifteen (15) business days following the transmission by either party of the notice
referred to in Section 12.13.1, an arbitrator shall be appointed in accordance with the then existing Rules of Conciliation and Arbitration of the International Chamber of Commerce (the
"Rules"), if for any reason an Arbitrator cannot be appointed in this manner, this Section 12.13.2 shall cease to apply to the dispute, controversy or claim in question and any party may apply
to a court of competent jurisdiction for the settlement thereof;

	12.13.3
	all
arbitration authorized by this Agreement shall be conducted in accordance with the Rules, that are not inconsistent with the terms of this Agreement;

	12.13.4
	decisions
and awards rendered by arbitration authorized by this Agreement shall be final and binding against the Purchaser and the Vendors and may be entered and enforced by
either the Purchaser or the Vendor in any court having jurisdiction. The Purchaser and the Vendors hereby irrevocably consent and submit to the jurisdiction of such court for purposes of such
enforcement;

	12.13.5
	in
the event either the Purchaser or the Vendors do not reasonably comply with a final decision or award made by the arbitrator, such non-complying party shall bear
all costs and expenses, including attorney's fees, incurred by the other party in obtaining enforcement of the decision or award; 

13

 

	12.13.6
	during
any period of arbitration concerning this Agreement or any part thereof, this Agreement shall remain in full force and effect and all terms shall be complied with by both
the Purchaser and the Vendors;

	12.13.7
	the
arbitrator shall not add to, subtract from, or modify any of the terms or conditions of the Agreement;

	12.13.8
	the
arbitrator shall use its best efforts (i) to complete the process of arbitration including the arbitration hearing within one hundred and twenty (120) days of
his nomination and (ii) to render a decision or an award within thirty (30) days after the close of arbitration hearings;

	12.13.9
	each
party shall pay its own costs related to the arbitration unless the arbitrator decides otherwise;

	12.13.10
	all
arbitration proceedings authorized by this Agreement shall be conducted (i) in the English language and all documents referred to shall be in English or French only,
and (ii) in Italy if the arbitration is requested by the Purchaser or in Montreal, Quebec if the arbitration is requested by either of the Vendors;

	12.13.11
	this
Section 12.13 shall not apply in cases where a party is seeking, as a remedy to a dispute, controversy or claim, the issue of an interlocutory injunction or another
similar remedy and except for the purpose of filing the award or obtaining an order of enforcement, as the case may be, for the purpose of rendering the award executory. 

        [Remainder
of this page intentionally left blank. The next page is the signature page.] 

14

 
 

Signature page 1 of 1    
    

 
 

SIGNATURES    
    

        IN WITNESS WHEREOF, each of the parties has caused this Agreement to be executed on its behalf by a duly
authorised officer all as of the date first written above. 

	(Vendor 1)	 	SIRTON PHARMACEUTICALS S.p.A
	

 	
 	

Per:	
 	

 
	 	 	 	 	

	 	 	Name:	 	 
	 	 	Title:	 	 
	

(Vendor 2)	
 	

 	
 	

 
	 	 	GENTIUM S.p.A.
	

 	
 	

Per:	
 	

 
	 	 	 	 	

	 	 	Name:	 	 
	 	 	Title:	 	 
	

(Purchaser)	
 	
AXCAN PHARMA INC.
	

 	
 	

Per:	
 	

/s/  LEON F GOSSELIN      

	 	 	Name:	 	LEON F GOSSELIN
	 	 	Title:	 	PRESIDENT AND CEO
	 (Signatures end)

 
 

SCHEDULE 1.1.2    
    
    COMMERCIAL ADVANTAGES    
    

 
 

SEE ATTACHED DOCUMENT    
    

EP SPRAY SYSTEM

EP SPRAY SYSTEM SA-30 RUE DU PLAN-CH-2002 NEUCHATEL

TEL ??? 25 07 22 FAX 03? 24 4? 07

[ILLEGIBLE]  

	 	 	Crinos

Industra Farmacobiologica S.p.A

A l'att. M. Arcidiacono

Plazza Settembre, 2
	

 	
 	
I-22079 Villa Guardia (Como)Italy
	

N ref GB        V.réf.	
 	

Neuchâtel, le 21 décembre 1995

Cher Monsieur Arcidiacono, 

        Nous
vous remercions de l'intérét que vous manifestez pour nos produits et de l'excellent accueil que vous nous avez réservé
en votre usine en date du 12 ct. Suite à votre demande et à nos discussions au sujet du dossier "Azalan", nous avons bien pris note de: 

        1.     Crinos
travaille sur la mise au point d'un produit dont le but est le traitement de la maladie de "Crone" ainsi que la colyte ulcérative, produit qui sera
conditionné chez Crinos et commercialisé principalement en Europe et aux USA. Sur le plan mondial, le groupe Pharmacia a été
approché pour la commercialisation. 

        2.     Le
principe actif utilisé dans cette présentation est à base de "Mesalazina" ou autre produit pharmaceutique. 

        3.     Crinos
souhaite obtenir de EP Spray System SA un avantage concurrentiel de 10 (dix) années à partir de la date de lancement pour chaque
pays, pour la fourniture du systéme de diffusion EP Spray System. 

        L'avantage
concurrentiel est valable sous les conditions suivantes: 

        a)    Dans
le cadre de l'application de produit à base de "Mesalazina" ou autre produit pharmaceutique par voie rectale en combinaison avec le traitement de la
maladie de "Crone" ainsi que la colyte ulcérative 

        b)    Crinos
communiquera au préalable à EP Spray System SA, les volumes de vente budgétés (en
unités) pour la présentation en question. 

        En
çonséquence, et dans le cadre de ce qui précéde, EP Spray System SA donne son accord de principe à la
société Crinos Industria Farmabiologica S.p.A, pour un avantage concurrentiel concernant la fourniture de son système de diffusion. 

        Nous
vous remercions de bien vouloir nous tenir au courant sur le suivi donné à cette affaire. 

        Avec
nos sincères salutations. 

EP SPRAY SYSTEM®  

	/s/  PIET MOLEMANS      
 Piet Molemans

Directeur Général	 	/s/  GEORGES BOUILLE      
 Georges Bouille

Sales & Marketing

Copie: EP Spray System Italia Spa Mr N. Allegri.  

	FAX-Message	 	EP SPRAY SYSTEM®
	

EP SPRAY SYSTEM SA	
 	

 	
 	

 
	30, Rue du Plan	 	Phone:	 	(++41) 32 727 62 62
	CH-2002 Neuchâtel (Switzerland)	 	Fax:	 	(++41) 32 727 62 63
	

	à/te:	 	Company	 	de/from:	 	G. Bouille/cd
	 	 	To whom it may concern	 	date:	 	le 10.1.2001
	

Copy:	
 	

Crinos, I-Villa Guardia	
 	

page(s):	
 	

1
	 	 	Mr. Cuccia	 	conc./Re:	 	Competitive advantage
	

Dear Sirs, 

        We
refer to the EP Spray System supply agreement currently in force between EP Spray System and Crinos for the use of the dispensing system for the product based on Mesalazina in
connection with Chron disease and ulcerative cholitis. 

        We
confirm that EP Spray System SA will extend the supply agreement and all supply conditions contained therein to any Crinos' Licensee, and deliver the system, immediately upon request,
to Crinos or a certified Licensee. 

        All
conditions extended will be the same as those applied to Crinos at the moment of extension of the supply agreement. 

        With
our very best regards, 

EP SPRAY SYSTEM®  

	/s/  PIET MOLEMANS      
 Piet Molemans

General Director	 	/s/  GEORGES BOUILLE      
 Georges Bouille

Sales & Marketing Director

 
 

SCHEDULE 1.1.4    
    
    EUROPEAN COUNTRIES    
    
  
  
  
  SEE ATTACHED DOCUMENT    

MONDO 53  

 
  RIASSUNTO POLITICO-STATISTICO    
    

	Stati, Territori, dipendenze*

e (capitali)

	 	Superf.

kmq
	 	Popol.

(stima 1997)
	 	D.

	Albania (Tirana)	 	28 748	 	3 293 000	 	115
	Andorra (Andorra la Vella)	 	453	 	65 000	 	143
	Austria (Vienna)	 	83 859	 	8 087 000	 	96
	Belgio (Bruxelles)	 	30 528	 	10 189 000	 	334
	Bielorussia (Mensk)	 	207 600	 	10 360 000	 	50
	Bosnia ed Erzegovina (Sarajevo)	 	51 129	 	3 124 000	 	61
	Bulgaria (Solia)	 	110 994	 	8 329 000	 	75
	Ceca, Repubblica (Praga)	 	78 865	 	10 307 000	 	130
	Croazia (Zagabria)	 	56 610	 	4 774 000	 	84
	Danimarca (Copenaghen)	 	44 493	 	5 319 000	 	120
	Estonia (Tallinn)	 	45 227	 	1 463 000	 	32
	Finlandia (Helsinki)	 	338 145	 	5 145 000	 	15
	Francia (Parigi)	 	543 965	 	58 616 000	 	108
	Germania (Berlino)	 	357 021	 	82 012 000	 	230
	Grecia (Atene)	 	131 957	 	10 541 000	 	80
	Irlanda (Dublino)	 	70 285	 	3 644 000	 	52
	Islanda (Reykjavik)	 	102 819	 	271 000	 	3
	Italia (Roma)	 	301 308	 	57 512 000	 	190
	Iugoslavia (Belgrado)	 	102 173	 	10 632 000	 	104
	Kazakistan parte europea	 	148 715	 	664 000	 	4
	Lettonia (Riga)	 	64 610	 	2 472 000	 	38
	Liechtenstein (Vaduz)	 	160	 	31 000	 	195
	Lituania (Vilnius)	 	65 300	 	3 706 000	 	57
	Lussemburgo (Lussemburgo)	 	2 586	 	420 000	 	162
	Macedonia (Skopje)	 	25 713	 	1 984 000	 	77
	Malta (Vallerta)	 	316	 	375 000	 	1 188
	Moldova (Chioináu)	 	33 700	 	4 362 000	 	129
	Monaco (Monaco)	 	2	 	32 000	 	16 359
	Norvegia (Osio)	 	323 758	 	4 392 000	 	14
	Svalbard e lan Mayen	 	63 080	 	3 000	 	—
	Paesi Bassi (Amsterdam)	 	41 526	 	15 567 000	 	375
	Polonia (Varsavia)	 	312 685	 	38 802 000	 	124
	Portogallo (Lisbona)	 	91 831	 	9 943 000	 	108
	Regno Unito (Londra)	 	244 110	 	58 919 000	 	241
	Is. di Man (Douglas)	 	588	 	72 000	 	122
	Is. del Canale (St. Peter Port)	 	?195	 	?147 000	 	?754
	Gibilterra* (Gibilterra)	 	6	 	27 000	 	4 500
	Romania (Bucarest)	 	238 391	 	22 572 000	 	95
	Russia parte europea (Mosca)	 	4 238 500	 	114 564 000	 	27
	San Marino (San Marino)	 	61	 	26 000	 	426
	Slovacchia (Bratislava)	 	49 035	 	5 404 000	 	110
	Slovenia (Lubiana)	 	20 258	 	1 955 000	 	97
	Spagna (Madrid)	 	505 989	 	39 323 000	 	78
	Svezia (Stoccolma)	 	449 964	 	8 844 000	 	19
	Svizzera (Berna)	 	41 285	 	7 116 000	 	172
	Turchia parte europea	 	23 764	 	6 710 000	 	274
	Ucraine (Kiev)	 	603 700	 	50 893 000	 	84
	Ungheria (Budapest)	 	93 030	 	10 174 000	 	109
	Vaticano, Cittá del	 	0,44	 	1 000	 	2 273
	 	Europa	 	?10 369 034	 	703 205 000	 	68
	dati 1996    [ILLEGIBLE] comprese; Azzorre, Madeira, Canarie, Isole asiatiche delia Grecia	 	 

 
 

SCHEDULE 1.1.5    
    
    GEL FORMULATION    
    
  
  
  
  SEE ATTACHED DOCUMENT    

 
 

PARTE II B    
    
    PROCEDIMENTO DI FABBRICAZIONE    
    

FORMULA DI FABBRICAZIONE  

        Per nu lotto di 420 litri pari a 1000 coufezioni (contenenti 7 flaconi da 60 ml cad.) sono
necessari:

	 
	 	conc.

2 g/60 ml
	 	conc.

4 g/60 ml

	Acido 5 aminosalicilico

(Mesalazina)	 	Kg	 	14,00	 	28,00
	Disodio edetato	 	Kg	 	0,420	 	0,420
	Sodio acetato 3 H2O (F.U.)

    	 	Kg	 	4,522	 	4,522
	Sodio metabisolfito	 	Kg	 	2,100	 	2,100
	Idrossietilcellulosa	 	Kg	 	0,3045	 	0,3045
	Avicel RC 591	 	Kg	 	5,880	 	5,880
	Acido acetico glaciale q.b. a

(teorico: litri 1,022)	 	pH	 	4,5-5,1	 	pH 4,5-5,1
	Acqua depurata q.b. a	 	1	 	420	 	420

PROCEDIMENTO DI FABBRICAZIONE  

        Preparare in una planetaria una sospensione di Avicel RC 591 in acqua depurata. 

        Ottenere
il vuoto ed aggiungere sotto vivace agitazione il p.a. Mesalazina. Dopo completa dispersione aggiungere una soluzione (ottenuta a parte) di Idrossietilcellulosa in acqua a
45°C. Aggiungere quindi la soluzione tampone formata da Sodio Acetato, Acido Acetico e acqua depurata. Sciogliere il Sodio Edetato e il Sodio Metabisolfito. Diluire a volume se necessario. 

CONVALIDA DEL PROCEDIMENTO  

        Sono stati già prodotti 4 lotti pilota da 10 litri presso la Tecnica Farmaceutica. 

        Non
sono stati individuati passaggi critici durante la preparazione (**). 

        Dopo
l'esecuzione di 3 lotti industriali sarà nostra cura segnalare a codesto Onorevole Ministero i risultati della convalida di procedimento. 

	**
	N.B.
in questi casi il confezionamento finale in bombole spray è stato effettuato presso la ditta EP Spray di Neuchatel (CH) depositaria del brevetto di confezionamento.
I lotti di produzione verranno approntati completamente presso Crinos utilizzando gli stessi impianti di inflaconamento utilizzati dalla ditta EP Spray stessa. 

 
 

SCHEDULE 1.1.12    
    
    PATENTS    
    

 
 

SEE ATTACHED DOCUMENT    
    

	Invention Data	 	 	 	lunedi 7 ottobre 2002
	

  
 	
 	

 	
 	

 

	Country Applications
 
	 	 
	 	 
	 	 
	 	 

	Ctry
	 	Sub

Case
	 	Case

Type
	 	Status
	 	Application

Number
	 	Filing

Date
	 	Patent

Number
	 	Issue

Date

	IT	 	 	 	EPC	 	Granted	 	96110263.9	 	26-giu-1996	 	765664	 	03-apr-2002
	LU	 	 	 	EPC	 	Granted	 	96110263.9	 	26-giu-1996	 	765664	 	03-apr-2002
	EP	 	 	 	ORD	 	Nationized	 	96110263.9	 	26-giu-1996	 	765664	 	03-apr-2002
	IT	 	PRI	 	ORD	 	Granted	 	MI95A001987	 	28-set-1995	 	01277663	 	11-nov-1997
	JP	 	 	 	ORD	 	Pending	 	250402/96	 	20-set-1996	 	 	 	 
	US	 	 	 	ORD	 	Granted	 	08/722.720	 	30-set-1996	 	5731302	 	24-mar-1998
	GB	 	 	 	EPC	 	Granted	 	96110263.9	 	26-giu-1996	 	765664	 	03-apr-2002
	CH	 	 	 	EPC	 	Granted	 	96110263.9	 	26-giu-1996	 	765664	 	03-apr-2002
	ES	 	 	 	EPC	 	Granted	 	96110263.9	 	26-giu-1996	 	765664	 	03-apr-2002
	SE	 	 	 	EPC	 	Granted	 	96110263.9	 	26-giu-1996	 	765664	 	03-apr-2002
	PT	 	 	 	EPC	 	Granted	 	96110263.9	 	26-giu-1996	 	765664	 	03-apr-2002
	NL	 	 	 	EPC	 	Granted	 	96110263.9	 	26-giu-1996	 	765664	 	03-apr-2002
	IE	 	 	 	EPC	 	Granted	 	96110263.9	 	26-giu-1996	 	765664	 	03-apr-2002
	GR	 	 	 	EPC	 	Granted	 	96110263.9	 	26-giu-1996	 	765664	 	03-apr-2002
	FI	 	 	 	EPC	 	Granted	 	96110263.9	 	26-giu-1996	 	765664	 	03-apr-2002
	DK	 	 	 	EPC	 	Granted	 	96110263.9	 	26-giu-1996	 	765664	 	03-apr-2002
	BE	 	 	 	EPC	 	Granted	 	96110263.9	 	26-giu-1996	 	765664	 	03-apr-2002
	AT	 	 	 	EPC	 	Granted	 	96110263.9	 	26-giu-1996	 	765664	 	03-apr-2002
	DE	 	 	 	EPC	 	Granted	 	96110263.9	 	26-giu-1996	 	765664	 	03-apr-2002
	FR	 	 	 	EPC	 	Granted	 	96110263.9	 	26-giu-1996	 	765664	 	03-apr-2002

 
 

SCHEDULE 1.1.13
  PURCHASED PATENTS
  
  
  
  SEE ATTACHED DOCUMENT    

US005731302A

	United States Patent	 	[19]	 	[11]	 	Patent Number:	 	5,731,302
	Farolfi et al.	 	 	 	[45]	 	Date of Patent:	 	Mar. 24, 1998

	

[54]	
 	
STABLE AQUEOUS SUSPENSIONS OF MESALAZINE
	[75]	 	Inventors:	 	Giancarlo Farolfi, Como; Franco Lattuada; Laura Ferro, both of Milan, all of Italy
	[73]	 	Assignee:	 	Crinos Industria Farmacobiologica S.p.A., Villa Guardio, Italy
	[21]	 	Appl. No:	 	722,720
	[22]	 	Filed:	 	Sep. 30, 1996
	[30]	 	Foreign Application Priority Data

	 	 Sep 28, 1995    [IT]    Italy	 	MI95A1987
	[51]	 	Int. Cl.6	 	A61K 31/615
	[52]	 	U.S. Cl.	 	514/166
	[58]	 	Field of Search	 	514/166
	[56]	 	References Cited	 	 
	U.S. PATENT DOCUMENTS

	4,657,900	 	4/1987	 	Powell et al.	 	514/166
	4,664,256	 	5/1987	 	Halskov	 	206/213
	FOREIGN PATENT DOCUMENTS
	A 0 398 207	 	11/1990	 	European Pat. Off..	 	 
	A 0 468 555	 	1/1992	 	European Pat. Off..	 	 
	A-9101129	 	2/1991	 	WIPO.	 	 
	A-9212758	 	8/1992	 	WIPO.	 	 

Primary Examiner—Raymond Henley, III 

Attorney, Agent, or Firm—Nikaido, Marmelstein, Murray & Oram LLP 

	[57]	 	ABSTRACT	 	 

        The
invention discloses new compositions of mesalazine in the form of aqueous suspensions, characterized in that they are more stable than those of the prior art. The compositions
contain colloidal cellulose and one or more hydrophilic thickening agents. 

 
 

17 Claims, No Drawings    
    

 
 

STABLE AQUEOUS SUSPENSIONS OF
  MESALAZINE    
    

        Mesalazine (D.C.I.), or mesalamine (USAN), is the internationally adopted name for 5-aminosalicylic acid or 5-ASA. 

        This
compound is the active principle of pharmaceutical compositions for the therapy of Crohn's disease. 

        Pharmaceutical
compositions containing this compound are usually administered rectally, in the form of enemas, in order to provide a quicker therapeutic effect, since the active
principle can act directly on the intestinal mucosa from its delivery (A.B.R. Thomspon "New development in the use of 5-aminosalicylic acid in patients with inflammation bowel disease"
Aliment Pharmacol. Therap. 1991; 5 449-470). 

        Enemas
containing mesalazine are in the form of aqueous suspensions since the water solubility of the active principle is quite low at physiologic or slightly acidic pHs. As a
consequence of this the main issue to be solved is that of the intrinsic lack of stability of said compositions. 

        The
preparations of mesalazine (in the form of aqueous suspensions) disclosed in the literature of the field and/or currently sold on the market are prepared following the teachings of
the art that, as shown below, don't provide a satisfactory solution regarding the stability of said compositions. 

        Said
formulations contains thickening agents, sometimes surface active agents, and antioxidants (metabisulfite salts, usually having as the cation sodium or potassium ions),
bacteriostatic and sequestering agents (EDTA). Other usual excipients are inorganic acids or acetate buffers, wherein the salt cation is sodium or potassium. 

        Mesalazine
suspensions for topical use according to the present invention provide an expedient solution to the afore stated stability issue since they stay homogeneous longer than those
of the prior art. This affords the further advantage of avoiding the patient's direct intervention for homogenizing
extemporarily the formulation prior to topical application, as is recommended in the package inserts of mesalazine enemas. 

        According
to the present invention the above discussed stability issue is solved by formulating mesalazine with selected quantities of colloidal cellulose and of hydrophilic thickening
agents in aqueous suspensions. 

        Owing
to said excipients the new liquid formulations show a thixotropic behavior. 

        Hence
by applying a low shear to said colloidal solutions after storage for a period of time it is found that they exhibit absolute viscosities in the order of some thousands of mPa.s. 

        However,
when they are stirred and submitted to a moderate or high rate of shear (the latter event taking place, for example, when the composition is being dispensed from a pressurized
packaging or a plastic squeeze bottle), said suspensions become very flowing liquids with a viscosity of a few mPa.s. 

        Said
latter property of being a flowing liquid is an important feature of mesalazine enemas in view of the fact that they must exhibit a very good spreading inside the large
intestine (ref. ?.R. Wilding et al. "Colonic spreading of a non-chlorofluorocarbon mesalazine rectal foam enema in patients with quiescent ulcerative colitis" Aliment. Pharmacol. Ther.
1995, 9. 161-166; R. A. Vitti et al. "Quantitative distribution of radiolabeled 5-aminosalicylic acid enemas in patients with leftsided ulcerative colitis" Digestive Diseases
and Sciences vol. 34, 11, 1792-1797. 1989; M. Campieri et al. "Spread and distribution of 5-ASA colonic foam and 5-ASA enema in patient with ulcerative colitis"
Digestive Diseases and Sciences, 37, 12, 1890-1897, 1992; M. M. C. van Buul "Retrograde spread of therapeutic enemas in patients with inflammatory bowel disease" Hepato-Gastroenterol. 36
(1989) 199-201). 

        In
order to arrive at the present invention the applicant did thorough analytical work, performing the physical determinations and chemical analyses described below on the compositions
of the prior art 

featured
in Table 1. From said work it was determined that it is indeed desirable in this technical field to make available stable aqueous suspensions of mesalazine. 

        Coming
now to Table I. composition A is known from the patent application WO 92/12758 (page 18). The preparation and subsequent packaging in pressurized containers is described
under Example 1. 

        Compositions
B and C are pharmaceuticals currently available in Italy. 

 
 

TABLE I    
    

        Compositions of the mesalazine aqueous suspensions of the art

being referred to in the disclosure of the invention. 

	Excipient
	 	Compound
	 	Formulation A

(w/w %)
	 	Formulataion B

(w/v %)
	 	Formulation C

(w/w %)

	 	 	Mesalazine	 	6.67	 	4	 	6.67
	THICKENING	 	Colloidal silica	 	—	 	1.7	 	 
	AGENT	 	Xanium Gum	 	—	 	—	 	0.25
	 	 	Polyvinyipyrrolidone	 	—	 	0.84	 	—
	 	 	Carbopol ®	 	—	 	—	 	0.075
	 	 	Methylcellulose	 	—	 	0.84	 	—
	 	 	Hydroxyethylcellulose	 	1.20	 	—	 	 
	BACTERIOSTATIC	 	Sodium benzoale	 	—	 	0.38	 	0.1
	AGENT	 	 	 	 	 	 	 	 
	SEQUESTERING	 	EDTA disodium salt	 	0.1	 	—	 	0.1
	AGENT	 	 	 	 	 	 	 	 
	ANTIOXIDANT	 	Potassium	 	—	 	0.25	 	0.47
	 	 	Metabisulfite	 	 	 	 	 	 
	 	 	Sodium metabisulfite	 	0.5	 	—	 	—
	 	 	Potassium acetate	 	—	 	—	 	0.41
	 	 	Sodium acetate	 	0.82	 	—	 	—
	 	 	Phosphoric acid	 	—	 	0.1	 	—
	 	 	Acetic acid	 	enough	 	 	 	—
	SOLVENT	 	Distilled water	 	enough to g 100	 	enough to ml 100	 	enough to g 60
	CONTAINER	 	 	 	Pressurized aluminium container	 	Plastic squeeze bottle	 	Plastic squeeze bottle

 
 

TABLE II    
    

        Mesalazine aqueous suspensions of the art of Table 1. Recovery tests from

thereof packages and determination of the quantity of the active principle. 

	 
	 	 
	 	Formulation A
	 	Formulation B
	 	Formulation C

	 	 	Time elapsed from the manufacture of the preparations under test.	 	16 months	 	21 months	 	18 months
	1)	 	Recovery of the formulation after opening the containers; Quantity (by weight or volume):	 	61.7 g	 	102 ml	 	61 g
	 	 	Active principle content (% w/w or w/v)	 	6.67	 	4.08	 	6.76
	2)	 	Recovery of the formulation dispensed from the containers:

Quantity (by weight or volume):	 	59.2 g	 	91.2 ml	 	48.9 g
	 	 	Ratio as % (w/w or w/v) of said quantity to that of the recovery under 1):	 	95.9	 	89.4	 	80.2
	 	 	Active principle content (% w/w or w/v):	 	5.10	 	3.84	 	7.34
	3)	 	Recovery of the formulation left in the containers after dispensing:

Quantity (by weight or volume):	 	1.98 g	 	8.8 ml	 	11.5 g
	 	 	Ratio as % (w/w or w/v) of said quantity to that of the recovery under 1):	 	3.2	 	8.6	 	18.8
	 	 	Active principle content (% w/w or w/v);	 	39.30	 	7.27	 	4.43
	4)	 	Total grams recovered of the active principle/grams of masalazine recovered under point 1):	 	0.92	 	0.99	 	0.99

        In
Table II are reported the results obtained by performing the following physical determinations and chemical analyses: 

        A.
The Volume, or the corresponding weight of the mesalazine suspension obtained by opening the container and collecting the formulation in a beaker. For formulation A and C said
determination was carried out by weighing the container before and after being emptied. In the case of formulation B the density of the suspension was determined in order to convert the obtained
weight into the corresponding volume. 

        B.
HPLC assay of the active principle content in formulations A, B and C, performed as described below. 

        The
results obtained with said analyses are given under point 1) to Table II. 

        C.
The weight or volume of suspension obtained by emptying the containers according to the following procedures; 

        By
pressing the valve at the top of the container in the case of formulation A and by squeezing the plastic bottles in the case of formulations B and C 

        The
volume of formulation B was determined after assay of the bulk density. 

        D.
The quantity of mesalazine contained in said recovered suspensions. 

        The
results are given under point 2) of Table II. 

        E.
The residual volume of formulation left in the package and the quantity of the active principle contained therein (point 3 of Table II). 

        The
data of Table II represent the average of nine determinations. performed on three different samples, by repeating the assay in triplicate on each of them. 

        Thorough
shaking of the suspensions was made prior to said determinations. 

        Assay
of the active principle was made by HPLC on a liquid chromatograph equipped with a column Whatmann® PARSTISIL® 100 SCX 25 (strong cation exchanger) length,
at 25° C. and equilibrated at a flow rate of 1 m1/min. UV detector was set at a wavelength of 300 nm. The mobile phase, also referred to herein also as solvent solution or solvent, was
prepared by dissolving 8.38 g NaH2PO4 in 1.9 1 of bidistilled H2O and adding, when a clear solution was obtained, 80 ml of aceronitrile. pH was corrected to a value
of 2.0+0.1 with concentrated phosphoric acid. The solution was brought to a volume of 21 with bidistilled water and afterwards degassed. 

        The
standard solution of mesalazine was prepared by weighing directly in a 50 ml volumetric flask about 46 mg of mesalazine with a known titer, and then diluting up to volume with the
solvent. 

        The suspension thus obtained was sonicated until a clear liquid was obtained. 1 ml was diluted in a 50ml volumetric flask up to volume with the same solvent. The sample concentration was
of 0.0184 mg/ml. 

        For
assaying mesalazine in compositions A and C, about 700 mg of each formulation (containing 46 mg of the active principle) were weighed in a 50 ml volumetric flask and diluted
to volume with the mobile phase. Complete solubilization of said formulations was achieved by applying, alternately, sonication and stirring. 1 ml was pipetted out and diluted up to volume in a
50 ml volumetric flask with the solvent. 

        The
theoretical mesalazine concentration in said samples was about the same as that of the standard solution. The standard solution and the enema samples, diluted as described above,
were then injected into the liquid chromatograph. 

        For
formulation B the analytical procedure was somewhat different. Density of the sample was determined beforehand by means of a 25 ml picnometer. The first dilution step was effected as
described above for sample A and C. However, the second dilution was carried out in a 30 ml volumetric flask. 

        The
data given in Table 11 clearly show that the prior art mesalazine aqueous suspensions become unstable, with con-comitant precipitation of a solid residue
containing remarkable quantities of the active principle within a period varying from 1 to 2 years. The same Table also shows that after said precipitation the concentration of the active
principle in the supernatant is different from the one reported on the package label (Table I). 

        Regarding
the compounding of aqueous suspensions for pharmaceutical use, in the book "Remington: The Science and Practice of Pharmacy—Nineteenth Edition", volume 11 pages
1515-1516 it is stated that the most important excipients of said formulations are the viscosity agents and the surface active agents, the latter being functional to wet solid particles. 

        In
said reference are also given the following recipes, that accordingly can be used for the extemporaneous preparation of aqueous suspension: 

	A.
	Sodium
carboxymethyicellulose 2.5% tragacanth gum 1.25% and guar gum 0.5%.

	B.
	AVICEL®
RC 591 (colloidal cellulose, a co-precipitate of microcrystalline cellulose and sodium carboxymethylcellulose) stabilized with
hydroxypropylmethylcellulose, i.e. a thickening agent, being used as a suspending vehicle for propanolol and orphenadrine hydrochloride dispersions prepared from tablets.

	C.
	CARBOPOL®
934 (acrylic acid polymer, MW=3x106), at concentrations of 0.3% or greater, being used as a vehicle for suspending sulfamethazine 10% in water. 

        The
above cited prior art provides information for compounding suspensions which do not have a long shelf life. 

        Regarding
the recipes under points A and C, which are directed to the preparation of suspensions made using thickening agents or mixtures thereof, the applicant has determined that said
excipients alone do not make mesalazine suspensions stable. 

        Hence
even composition C, which comprises a thickening agent together with sulfamethazine, which is slightly soluble in water at neutral pH's and behaves in this aspect like
mesalazine, does not provide a useful teaching for compounding a stable mesalazine liquid composition. 

        Regarding
the inclusion of a surface active agent in the formulation, the applicant has determined that such an excipient does not influence the stability of mesalazine suspensions. 

        Though
the recipe given under point B discloses similar excipients as those of the composition of the instant invention, formulation B does not use the proportions required in the
present invention. 

        The
following considerations are believed to be of value for determining the novelty and inventive step of the present invention in view of the prior art teachings: 

	1)
	In
contrast to mesalazine, both propanolol and orphenadrine hydrochloride are soluble in water (Merck Index 1Oa Edition. page 7743, 7740, and page 6749-6752 respectively). 

        In
other words, what has been suspended in the above recipe are the excipients of the tablet formulations and not the active principles. Said excipients can likely be identified as the
usual water insoluble, or slightly water soluble common tablet excipients, i.e. diluents such as kaolin, starch, etc., lubricants such as magnesium or calcium stearate, etc. 

	2)
	The
information provided in the above reference does not disclose any selected quantity of colloidal cellulose and hydroxypropylcellulose. 

        Hence
the specific ranges of said components in the formulations of the instant invention could not be foreseen on the basis of said reference. Furthermore the instant limits, as it will
be shown herein later on, are critical in order to ensure both the stability of the suspension and the thixotropic effect, in particular the remarkable full of viscosity under a high rate of shear as
outlined above. 

        EP
A 0398207 discloses 5-ASA solutions containing the active principle together with its alkali metal or alkaline earth metal salt, an antioxidant and a metal complexing
agent. 

        EP
A 0468555 discloses a formulation in the form of a fluid vehicle able to generate a foam on rectal administration. Said suspension comprises at least one surfactant, a foaming
propellant, a suspending or solubilizing agent for the active principle and a foam thickener. 

        U.S.
Pat. No. 4,657,900 discloses an aqueous suspension of 5-ASA containing 0.25% bisulphite, which is stored in a single dose polyethylene bottle in a substantially
oxygen-free atmosphere, the plastic bottle being hermetically sealed in a plastic pouch. 

        The
disclosed compositions may also contain a natural or synthetic gum at concentrations from about 0.1% to 0.25% and also a flocculating agent to prevent caking of 5-ASA,
such as a water gellable cross linked polyacrylic acid at a concentration of about 0.05%-0.15%. 

        U.S.
Pat. No. 4,664,256 discloses a packaged enema solution or suspension consisting of 5-ASA, an antioxidant, a chelating agent and a buffering agent. The formulation
is
stored in a plastic bottle under an inert gas, and packaged in diffusion-tight light impervious bags made substantially of a plastic aluminum laminate. 

        WO
91/01129 discloses a solid composition for rectal administration that is reconstituted immediately before use by addition of water. Said solid composition may contain different active
principles (one of which is mesalazine), an antifoam additive, a thickening agent (e.g. cellulose derivatives), and other excipients such as wetting agents, compounds for adjusting the solution
isotonicity and osmolarity, diluents and low volatile liquids such as glycerine, polypropylene glycol, etc. Example 3 discloses solid compositions containing 5-ASA, sodium lauryl sulphate,
hydroxypropylmethylcellulose and polydispersed silica gel, Example 4 discloses a solid composition containing 5-ASA, vinylpirrolydone/vinyl acetate copolymer, hydroxypropylmethylcellulose,
sodium lauryl sulfate and an anti foaming agent. 

        All
of the above documents fail to disclose a thickening agent in combination with colloidal cellulose, which taken together stabilize mesalazine suspensions and hence yield a
homogeneous colloid system. 

        U.S.
Pat. No. 4,657,900 discloses a thickening agent (a natural or synthetic gum) in combination with a flocculating agent, i.e. a substance which brings about flocculation or
aggregation of the suspension (see "Remington's Pharmaceutical Sciences—fifteenth edition" page 325). In other words U.S. Pat. No. 4,657,900 teaches away from the present invention. 

        Regarding
WO 91/01129, this document requires the addition of water in order to suspend the starting solid formulation. Thus this document does not disclose a stable aqueous formulation
as in the 

present
application. In order to arrive at the composition of the present invention the applicant performed stability tests on formulations obtained by modifying composition A of Table 1, which was
chosen for this purpose since it was the simplest to prepare among those featured. 

        The
modifications made were based on the teachings of the above mentioned book "Remington: The Science and Practice of Pharmacy, 19th edition". 

        The
conclusions arrived at were the following: 

        It
is not possible, as detailed in example 2, to make stable mesalazine aqueous suspensions using only thickening agents. It was determined that even using about twice (i.e. 2.2%
w/w) the quantity of hydroxyethylcellulose as compared to that present in the original formulation A. despite the fact that
the suspension thus obtained was in the form of a thick gel with an absolute viscosity value ranging in the order of some thousands mPa.s. said formulation was still unstable. It was observed that
after storage in sealed glass containers at room temperature, for 1 month in the dark, a precipitate was separated. 

        This
lack of stability was further confirmed by assaying the active principle in the supernatant gel, which titer was found to be lowered to 92.9% as compared to that of the fresh
formulation. 

        The
addition to formulation A of a surface active agent, as detailed in example 3, does not appear to significantly improve the stability of mesalazine suspensions either. 

        This
example describes the preparation of an enema suspension obtained by increasing the quantity of hydroxyethylcellulose up to 2.0% in formulation A and then adding TWEEN®
20 in the amount of 0.25% w/w. 

        In
this case stability was qualitatively assayed by centrifuging an aliquot of the suspension at 4000 rpm for 15 minutes and inspecting the bottom of the test tubes. The presence of a
precipitate was noted. The titer of the active principle in the supernatant was found to be as low as 74.35% of the theoretical calculated based on the amount of mesalazine used in the preparation. 

        The
problem of obtaining aqueous suspensions of mesalazine with improved stability, as compared with those of the prior art has now been solved, according to the applicant's findings, by
compounding the aqueous suspensions of said active principle with a quantity of colloidal cellulose ranging from 1.2 to 1.6% (w/v of the composition), together with one or more hydrophilic thickening
agents in a ratio by weight (w/w) to colloidal cellulose of between 0.04 and 0.2, corresponding respectively to a percentage of 4% and 20%. The above range becomes, or is equivalent to,
0.048-0.32% w/v when the weight of the thickening agents, calculated on the lower and upper limit of the colloidal cellulose range, is divided by the total volume of the formulation and
the relevant percentages then determined. 

        Colloidal
cellulose, otherwise defined as water dispersible cellulose, is a mixture of cellulose with 8.3-18.8% w/w of carboxymethylcellulose (Handbook of Pharmaceutical
Excipients Second Edition 1994, page 86), suitable examples are AVICEL® RC 5910, AVICEL® RC 5810, AVICEL® CL-610. 

        The
thickening agents useful in the instant invention are hydrophilic polymers such as: carboxypolymethylene, sodium carboxymethylcellulose, hydroxyethylcellulose, xantan gum,
hydroxypropylmethylcellulose, methylcellulose, and carrageenan. 

        The
suspension according to the present application preferably also contains the usual excipients such as antioxidants, sequestering and bacteriostatic agents, buffering agents, and
inorganic acids. The pH is preferably between 4.5 and 5.1. 

        The
various ranges of colloidal cellulose and of the thickening agents have been determined from the results obtained in the experiments and analytical determinations described below. 

        In
the first set of tests, 99 different aqueous suspensions were prepared, each in the quantity of 1 liter and containing different concentrations of colloidal cellulose and of the
hydrophile thickening agent. In order to prepare them nine suspensions were compounded, each containing colloidal cellulose in the relevant percentages w/v (final concentration in 1 liter) of 1; 1.1;
1.2; 1.3; 1.4; 1.5; 1.6; 1.8; and 

2.0%.
From each of said nine suspensions were prepared eleven further formulations containing a thickening agent (hydroxyethylcellulose) in the following relevant percentages by weight referred to
colloidal cellulose: 2; 4; 6; 8; 10; 12; 14; 16; 18; 20, and 25%. Mesalazine and the other excipients were added as described in Example 4. 

        500
ml of each of the final 99 suspensions was transferred into capped glass containers having a diameter of 46 mm and height 56 mm (internal dimensions), while the remaining 500 ml
aliquot was used to fill 20 ml syringes (Stering® Artsana, Casnate Como) having a 1.2 mm (inner diameter) x38 mm (length) needle. The needle holder, forming one body with the flat bottom
of the syringe, had an internal diameter of 2.4 mm. 

        Both
the syringes and containers were then stored in the dark for one month at the following temperatures: 3° C., ambient temperature. 30° C. and 40°
C. Inspection of the content of the glass containers at the end of this period showed that a precipitate was present at the bottom of those glass containers filled with formulations having a quantity
of colloidal cellulose below 1.2% w/v. The precipitate was abundant in those suspensions conditioned at temperatures of 30° C. and 40° C. 

        It
was also ascertained that the phenomenon was independent of the added quantity of the thickener. 

        It
was furthermore determined that a quantity of cellulose above 1.2% w/v was not by itself enough to provide the desired stability, if concomitantly the weight ratio of the thickening
agent to colloidal cellulose was not 4% or higher. In the case of 1.2% w/v of cellulose this weight ratio of the thickener to said excipient corresponds to a percentage of 0.048% w/v of the total
volume solution. 

        It
was also observed that at concentrations of colloidal cellulose higher than 1.6% w/v the suspensions retained a high viscosity and the compositions had a gel-like
consistency after being manually extruded from the syringes and did not show the thixotropic behavior of the enemas of the present invention. 

        It
was also noted that by increasing the weight ratio of the thickening agent above 20% w/w of cellulose, or above 0.32% w/v calculated on the overall suspension in the case where the
colloidal cellulose quantity is 1.6% w/v, the extruded liquids resumed high values of viscosity very quickly. 

        This
is not considered desirable in view of the fact that mesalazine enemas are generally low viscosity liquids. The results obtained in the clinical pharmacological trial reported in
Example 7, demonstrate that the formulations of the present invention behave substantially as the mesalazine suspensions of the art. This suggests that the enemas of the present invention are able to
retain low viscosities for a fairly long time. It was hence concluded that it is important that the new mesalazine thixotropic compositions contain colloidal cellulose and the thickening agent in
appropriate quantities. 

        Reverting
to the experiments performed by the applicant on the formulations of Example 4, worth noting is that a few syringes taken from the lots containing a quantity of
colloidal cellulose between 1.2 and 1.6% and between 4% and 20% of the thickener (as percentage weight ratio to cellulose), after removal of the needle, were emptied in 4 seconds or less by
applying to the plunger at a weight between about 970 and 1100 mg. 

        Absolute
viscosity determinations performed on the same suspensions establish that the formulations satisfying the above referenced qualitative test had an absolute viscosity of 7 mPa.s
or lower when measured at the shear rate of 37.6 sec-1 at a temperature of 20° C. The viscometer used was a rotational viscometer Contraves Low Shear 30
[ILLEGIBLE] requipped with the measuring bob 1, dimensions 11x8 mm. The instrument was set on range 3, corresponding to a shear stress t
Pa 1% 0.01305. The volume of the formulations used for said determinations was about 700 ml. 

        Worth
noting is that absolute viscosities, under the same conditions, of compositions B and C (Table 1) were very near to the above limit. 

        Reverting
now to the further research work made on the instant formulations, in a second series of experiments it was determined in more detail, which composition of the suspension had
the best behavior in the syringe test. 

        According
to the recipe given in Example 4, were prepared 5 suspensions containing colloidal cellulose at concentrations of 1.2; 1.3; 1.4; 1.5; 1.6% w/v, respectively. From each of said
suspensions were then made 7 formulations containing a quantity of hydroxyethylcellulose in the lower half of the selected range, i.e. as w/w percentage to colloidal cellulose, of 4, 5, 6, 7, 8, 9,
and 10% respectively. 

        A
total of 35 samples were prepared. 

        From
the results obtained it was concluded that the compositions with very good thixotropic behavior and flowing properties contained 1.4% w/v of colloidal cellulose and a quantity of
thickening agent varying from 6% to 7% by weight of the colloidal cellulose or, otherwise said, in a percentage w/v on the overall composition from 0.084 to 0.098% (calculated on 1.4% w/v of colloidal
cellulose). 

        Taking
into account the results obtained in the aforementioned experiments it was decided to carry out a second set of stability tests, performed at room temperature for a time longer
than before, in order to check the actual shelf life of the new compositions. 

        Three
lots of enema formulations, as shown in Table III, were prepared according to Example 5, on the basis of the indications given in Example 4. 

        The
enemas were packed in pressurized containers under nitrogen gas by the same procedure described in the second part of Example 1. Each container was filled with a volume of enema of
60 ml, corresponding to 62 g of the formulation as established by former density determinations. Said quantity of 62 g was hence the theoretical content of each packaging on the basis of the recipe
used to prepare said suspensions. The filled containers were then stored at room temperature. Three samples were then taken for analysis at time zero and then, respectively, after one and two years.
The suspensions were discharged from the containers by pressing the valve stem and the weight and active principle content then determined. The weight of the residual suspension in the container was
also checked. In order to carry out this latter assay the packagings were emptied by pressing the actuator, then carefully weighed, opened and washed out with water and aqueous ethanol. Afterwards
they were dried in an oven at 30° C, and weighed again. 

        The
results of stability tests are given in Table IV and provide evidence that the new compositions of mesalazine are stable for two years. 

        One
further embodiment of the invention is the process for manufacturing the new aqueous suspensions of mesalazine. 

        Said
process, as shown in example 6, includes the following steps: 

        Dissolution
of colloidal cellulose and of the thickening agent in two separate aliquots of distilled water, said aliquots being 60% and 30% respectively of the total volume of water
needed for the preparation of the suspension. 

        Mixing
the two solutions and adding the other excipients of the formulation. 

        Adding
and suspending the active principle in said solution, under vacuum and stirring. 

        Adding
distilled water to the aqueous suspension in order to yield the final requested volume. 

        The
new formulations may be stored in squeeze bottles containing a volume of 60 ml with 2 or 4 g of mesalazine, or in containers pressurized with nitrogen. 

        In
the latter case particularly suitable are containers having a smaller bag filled with the suspension inside of a thin aluminum foil covered on both sides with plastic coatings. 

        In
this way the suspension is hermetically insulated from the propellant, so that the latter is excluded from being delivered into the intestine together with the formulation during
dispensing from the pressurized containers. 

 
 

BRIEF DESCRIPTION OF THE DRAWINGS    
    

        FIGS. 1A, 1B and 1C show the different rheological behavior (in ordinates the shear stress in Pascal and in abscissas shear rate in s-1) of three
compositions. Curve A refers to a formulation according to the instant invention having the composition of example 8, curves B and C refer to the formulations B and C featured in Table 1. Said
diagrams were obtained using the same rotational viscometer (Low Shear 30) described previously, and the same volume of solution in the measuring cup. The temperature was fixed at 20° C.
The range on which the instrument was set (range 5) corresponds to a shear stress t Pa 1% 0.0326. Each point of the curve is the average of 18 separate
determinations taken on the sample at intervals of 15 seconds. The sample was at first equilibrated for about 10 minutes in the measuring cup with the measuring bob dipped into the solution, rotating
at the selected shear stress. Within said time readings became fairly constant. Curve A features the thixotropic properties of the suspensions according to the invention. Curves B and C show that the
suspensions of the prior art containing mesalazine do not share, or share only to some extent, said property. 

 
 

TABLE III    
    

        Composition w/v of the formulations used in the second series of stability tests. 

	 
	 	Form.

I A
	 	Form.

I B
	 	Form.

I C
	 	Form.

II A
	 	Form.

II B
	 	Form.

II C
	 	Form.

III A
	 	Form.

III B
	 	Form.

III C

	Mesalazine	 	6.67	 	6.67	 	6.67	 	6.67	 	6.67	 	6.67	 	6.67	 	6.67	 	6.67
	Colloidal cellulose (C.C.)	 	1.2	 	1.2	 	1.2	 	1.4	 	1.4	 	1.4	 	1.6	 	1.6	 	1.6
	Hydroxyethyl cellulose (H.C.)	 	0.048	 	0.084	 	0.120	 	0.056	 	0.098	 	0.140	 	0.064	 	0.112	 	0.16
	(H.C.)/(C.C.) ratio % w/w	 	4	 	7	 	10	 	4	 	7	 	10	 	4	 	7	 	10
	Sodium acetate	 	0.8	 	0.8	 	0.8	 	0.8	 	0.8	 	0.8	 	0.8	 	0.8	 	0.8
	EDTA Disodium salt	 	0.10	 	0.10	 	0.10	 	0.10	 	0.10	 	0.10	 	0.10	 	0.10	 	0.10
	Sodium metabisulfite	 	0.5	 	0.5	 	0.5	 	0.5	 	0.5	 	0.5	 	0.5	 	0.5	 	0.5
	Acetic acid	 	0.26	 	0.26	 	0.26	 	0.26	 	0.26	 	0.26	 	0.26	 	0.26	 	0.26

 
 

TABLE IV    
    

Results
obtained in the stability tests effected at room temperature on the compositions given in preceding Table III. Data herein provided are the average of three determinations.

Abbreviations used in the Table

Form. = formulation: — Form. rec. = Formulation recovered (figures in grams) by emptying the container in a beaker after pressing the valve; — % on the theor. content =
percentage by weight of the formulation recovered on the theoretical content; — Mesalazine titre = titre of mesalazine in the 

quantity
recovered of the formulation; — Residue g. = residual grams of formulation found after opening and emptying the container. 

	 
	 	Form.

IA
	 	Form.

I B
	 	Form.

I C
	 	Form.

II A
	 	Form.

II B
	 	Form.

II C
	 	Form.

III A
	 	Form.

III B
	 	Form.

III C

	TIME ZERO	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Form, rec. (g.)	 	60.84	 	60.96	 	61.03	 	60.93	 	61.10	 	60.86	 	60.99	 	61.03	 	61.05
	% on the theor. content	 	98.2	 	98.4	 	98.5	 	98.4	 	98.6	 	98.2	 	98.5	 	98.5	 	98.6
	Mesalazine titre	 	6.66	 	6.67	 	6.67	 	6.66	 	6.68	 	6.67	 	6.67	 	6.67	 	6.67
	Residue g.	 	0.78	 	0.74	 	0.80	 	0.75	 	0.67	 	0.77	 	0.64	 	0.82	 	0.72
	

ONE YEAR	
 	

 	
 	

 	
 	

 	
 	

 	
 	

 	
 	

 	
 	

 	
 	

 	
 	

 
	Form, rec. (g.)	 	61.06	 	60.86	 	61.15	 	60.85	 	60.98	 	60.94	 	60.85	 	61.10	 	60.88
	% on the theor. content	 	98.6	 	98.2	 	98.7	 	98.2	 	98.4	 	98.4	 	98.2	 	98.6	 	98.5
	Mesalazine titre	 	6.66	 	6.65	 	6.66	 	6.67	 	6.65	 	6.66	 	6.65	 	6.67	 	6.68
	Residue g.	 	0.70	 	0.80	 	0.65	 	0.78	 	0.79	 	0.78	 	0.89	 	0.65	 	0.86
	

TWO YEARS	
 	

 	
 	

 	
 	

 	
 	

 	
 	

 	
 	

 	
 	

 	
 	

 	
 	

 
	Form, rec. (g.)	 	60.87	 	60.97	 	60.85	 	60.99	 	61.02	 	60.93	 	61.14	 	61.07	 	60.97
	% on the theor. content	 	98.2	 	98.4	 	98.2	 	98.5	 	98.5	 	98.4	 	98.7	 	98.6	 	98.4
	Mesalazine titre	 	6.68	 	6.67	 	6.66	 	6.65	 	6.67	 	6.67	 	6.67	 	6.67	 	6.65
	Residue g.	 	0.80	 	0.75	 	0.83	 	0.74	 	0.78	 	0.73	 	0.65	 	0.67	 	0.80

 
 

Example 1    
    

        Preparation of formulation A of Table 1. 

        In
4.8 kg of distilled water, in a nitrogen atmosphere, were dissolved 5 g of EDTA and 41.0 g of anhydrous sodium acetate. The pH was then adjusted to 4.8 with about 19 ml of glacial
acetic acid, 25 g of sodium metabisulphite was then added. The solution was transferred into a reaction vessel which was then hermetically closed. A vacuum was afterwards effected (300-400
mm Hg).
Under a vigorous stirring 60 g of hydroxyethylcellulose (NATROSOL® 250HHR) was dissolved. The solution was then warmed up to 45o C. and at that temperature exhibited a
gel-like consistency. The temperature was then lowered to 25o-35oC. 333.5 g of mesalazine were added. A vacuum was set up again and vigorous
stirring started. 

        5148
g (volume about 5040 ml) of a suspension according to formulation A were obtained. The suspension was then divided into 50 packages pressurized with nitrogen gas (9-10
Atm) having a diameter of 35 mm and a volume of 110 ml. Each container was filled with 60 ml. 

 
 

Example 2    
    

        Preparation of a suspension containing 6.67% (w/w) mesalazine, 2.2% of thickening agent (hydroxyethylcellulose), 0.1% disodium EDTA, 0.5% sodium metabisulphite,
0.67% sodium acetate. 

        Under a nitrogen atmosphere, 6 g of disodium EDTA, 40.35 g of anhydrous sodium acetate, about 17 ml of glacial acetic acid to bring the pH to 4.83, and 30 g of sodium metabisulphite were
dissolved in 5.7 kg of distilled water. 120 g of hydroxyethylcellulose (NATROSOL® 250HHR) was then added with stirring and the solution was warmed at 50o C, under moderate
agitation until a gel was formed and then transferred into a vessel that was afterwards tightly closed. Vacuum was therein effected and the viscous solution was heated at 50o C, under
stirring. The mass was slowly cooled and, under agitation, 400.2 g of mesalazine added. The suspension was then milled in a colloid mill and collected in a container under a nitrogen atmosphere. 5.01
kg (about 4910 ml) of the product was obtained. The assayed titer of the active principle corresponded to the theoretical. 

        One
liter of said preparation was divided in 60 ml aliquots: into 16-100 ml glass vessels having an inner diameter of 4.6 cm (external 6 cm) and height 56 mm, afterwards the
vessels were tightly sealed and stored at 25o C, in the dark. After one month three containers were taken out and carefully emptied in separate beakers. The presence of a solid residue
at the bottom was observed. HPLC analysis of the active principle performed on the supernatants showed that the titer of mesalazine was 93.9% of that found at time zero. 

 
 

Example 3    
    

        Preparation of a suspension containing 6.67% (w/w) mesalazine, 2% thickening agent (hydroxyethylcellulose—NATROSOL® 250HHR). 0.25% surface
active agent (Tween® 20), 0.1% disodium EDTA. 0.67% sodium acetate, and 0.5% sodium metabisulphite. 

        In
440 g of distilled water were dissolved 1.25 g of TWEEN® 20, 0.5 g of EDTA disodium salt, and 3.36 g of anhydrous sodium acetate. The pH was corrected to 4.8 with about
1.4 ml of glacial acetic acid and 2.5 g of sodium metabisulphite was added. 10 g of hydroxyethylcellulose and then 33.33 g of the active principle were admixed and dissolved in the solution according
to the procedure described in example 1. Distilled water was then added to yield 500 g. Aliquots of the freshly prepared suspension were transferred into 4-100 ml centrifuge tubes and
centrifugation effected at 4000 rpm for 15 minutes. After careful removal of the supernatant a solid residue was found at the bottom of the test tubes. Said residue contained a fairly large amount of
mesalazine, as shown by assaying (HPLC) the titer of the active principle in the supernatant. This residue was found to be 74.35% of that expected on the basis of the quantity used for preparing the
suspension. 

 
 

Example 4    
    

        Preparation of mesalazine suspensions having colloidal cellulose concentrations w/v of 1; 1.1; 1.2; 1.3; 1.4; 1.5; 1.6; 1.8 and 2.0% respectively, and thickening
agent concentrations, as percentage by weight to the quantity of colloidal cellulose, of 2; 4; 6; 8; 10; 12; 14; 16; 18, 20 and 25% respectively, mesalazine 6.67% w/v, sodium acetate 0.8% w/v,
disodium EDTA 0.1% w/v, and sodium metabisulphite 0.5% w/v. 

        Each
suspension was prepared in a standard quantity of 1 liter using the following procedure. 9 different suspensions of colloidal cellulose (AVICEL® RC 591) were prepared by
using a 10 liter reaction vessel, into which were transferred aliquots of 7.5 liters of water to which were separately added, 125 g, 137.5 g, 150 g, 162.5 g, 175 g, 187.5 g, 200 g, 225 g, or 250 g of
the above compound. Stirring was continued until a colloidal solution was obtained. 

        On
the basis of the above colloidal cellulose quantities in a 600 ml aliquot of each of said nine suspensions were contained, respectively, 10 g, 11 g, 12 g, 13 g, 14 g, 15 g, 16 g, 18 g
or 20 g of the compound. 

        Separately,
in 300 ml aliquots of distilled water a quantity of hydroxyethylcellulose (NATROSOL® 250HHR) was dissolved in order to yield the weight ratios to colloidal
cellulose discussed above. When a clear solution of the thickener had been formed, mixing was effected with the corresponding 600 ml aliquot containing the quantity of colloidal cellulose on which the
amount of hydroxyethylcellulose had been calculated. To each of the solutions thus obtained were then added 8 g of anhydrous sodium 

acetate
and 2-3 ml of glacial acetic acid. The final pH was about 4.8.1 g of EDTA disodium salt and 5 g of sodium metabisulphite were then added. 

        In
a nitrogen atmosphere and under stirring each solution was admixed with 66.7 g of 5-ASA, stirring was continued until a homogeneous dispersion was obtained. The suspension
was then brought to the volume of 1 liter with distilled water. 

        Each
suspension was then divided into two parts. Half were used to fill 100 ml glass containers having the dimensions set forth in Example 2. With the other half were filled syringes
(syringes Steringa®, Artsana, Casnate Como) having the characteristics discussed above. 

        The
glass containers and syringes filled with the same preparation were divided into 4 groups which were then stored, respectively, at 3o C., room temperature,
30o C, and 40o C, for one month. 

        At
the end of the storage period the glass containers were turned carefully upside down in order to ascertain whether a precipitate had collected at the bottom, and it was found that a
solid residue was present in all of those samples having a colloidal cellulose content of less than 1.2% w/v. The precipitate was particularly abundant in those samples stored at 30o C,
and 40o C. The viscosities of the suspensions from which no precipitate had been separated were checked. A preliminary qualitative test was carried out by emptying the filled syringes
after removal of the needle. At the same time absolute viscosity determinations were performed on some of the samples. Both assays are described above. 

        The
formulations having a quantity of colloidal cellulose higher than 1.6% were quite viscous and in the above reported qualitative test of emptying the filled syringes did not provide
the desired results. 

        The
formulation containing a quantity of the thickening agent, given in ratio by weight to colloidal cellulose, higher than the upper limit of 20% i.e. 25%, showed a marked thixotropy
since they recovered very early high viscosity values. This was considered an undesirable feature for the reasons stated above. Furthermore, it was also observed that when the ratio of the thickening
agent to colloidal cellulose was below 4% the composition was not stable. 

 
 

Example 5    
    

        Preparation of nine mesalazine suspensions containing colloidal cellulose in quantities respectively of 1.2; 1.4; and 1.6% w/v calculated on the overall
composition, a thickening agent (hydroxyethylcellulose) in quantities of 4; 7 and 10% w/w calculated on each of the above percentage w/v of colloidal cellulose, mesalazine 6.67%, sodium acetate 0.8%,
disodium EDTA 0.1%, and sodium metabisulphite 0.5%. 

        Each
suspension was prepared in a standard quantity of 1 liter using the following procedure. Under stirring in 600 ml separate aliquots of distilled water, was suspended colloidal
cellulose (AVICEL® RC 591) in the quantities, respectively, of 12 g, 14 g, and 16 g. Stirring was continued until a colloidal suspention was obtained. 

        For
each of the above concentrations were prepared 3-600 ml samples. Separately prepared were 300 ml aqueous solutions of hydroxyethylcellulose (NATROSOL® 250HHR)
containing respectively the following quantities of the compound 

        A)   480
mg, 840 mg and 1200 mg. 

        B)    560,
980 and 1400 mg. 

        C)    640,
1120, 1600 mg. 

        The
solutions of group A were separately admixed with 600 ml of the suspension containing 1.2% w/v colloidal cellulose. 

        Those
of group B were separately admixed with 600 ml of the suspension containing 1.4% w/v colloidal cellulose. 

        Those
of group C were separately admixed with 600 ml of the suspension containing 1.6% w/v colloidal cellulose. 

        To
the suspensions thus obtained were then added 8 g of anhydrous sodium acetate and 2-3 ml of glacial acetic acid. The final pH was of about 4.8. 1 g of EDTA disodium salt
and 5 g of sodium metabisulphite were then added. 

        In
a nitrogen atmosphere and under stirring each solution was admixed with 66.7 g of 5-ASA. continuing afterwards stirring until an homogeneous dispersion was obtained, which
was then brought to the volume of 1 1 with distilled water. 

        Density
determinations made with the aid of a 25 ml picnometer at the ambient temperature afforded the average value of 1.03. 

        Said
suspensions were then transferred into pressurized packagings, each containing 60 ml of the formulations. The containers were the same as those described in example 1. 

 
 

Example 6    
    

        Preparation of an industrial batch of the formulation of the invention having the following composition in 60 ml of the final product (percentages, wherein not
otherwise indicated, are in w/v): Mesalazine 6.67%, colloidal cellulose 1.4%, hydroxyethylcellulose 7% w/w to colloidal cellulose, sodium acetate trihydrate 1.08%, sodium metabisulfite 0.5%, disodium
EDTA 0.1%, glacial acetic acid enough to pH 4.8. 

        In
a 600 L stainless steel reaction vessel 5.880 Kg of colloidal cellulose (AVICEL® RC 591) was suspended in 2521 of distilled water under vigorous agitation. The process was
eased by operating concomitantly a colloid mill. In a different aliquot of 126 1 of warm water at 45oC., in a 200 liter stainless steel vessel, were dissolved under stirring 0.411 Kg of
hydroxyethylcellulose. The solution was then cooled to room temperature and added to the cellulose suspension under thorough mixing. To the resulting colloidal solution, were then added 0.420 kg of
EDTA disodium salt, 4.522 Kg of sodium acetate trihydrate, and 2.100 Kg of sodium metabisufite. The vessel was then hermetically closed and vacuum was therein made (200 mm Hg). 14 Kg of mesalazine was
then added under stirring. About 1 1 of glacial acetic acid was then added and the solution brought to the final volume of 420 1 with distilled water. 

        The
above quantity can be used to produce 7000 pressure packings containing 60 ml each of the suspension of the invention. 

 
 

Example 7    
    

        Pharmacological clinical trial with the new compositions and assessment of the distance travelled in the large intestine. 

        For
said clinical trial the active principle 5-ASA had been radioactively labelled with 100 MegaBequerel of colloidal99[ILLEGIBLE] Tc
sulfide (Technetiurn isotope 99 sulfide). Since this salt has an half-life of only 6 hours, the compositions were radioactively labelled within 2 hours of their
administration. 

        Twelve
patients aged between 18 and 70 years were admitted to the trial, of both sexes. Admission criteria were as follows: Distal ulcerative colitis progressed up to at least 20
cm from the anus but not above the splenic flexure (established by colonoscopy at least 7 days before the beginning of the trial), low or moderate inflammation, five or more diarrhea
episodes/day with blood and mucous in at least one discharge, abdominal pain, tachycardia, anemia, anorexia and vomiting. 

        In
6 out of 12 patients the disease was ascertained to occur in the sigmoid-rectum portion of the intestine and in the others in the colon. 48 hours before the start of the trial,
therapy with sulfasalazine or other active principle related to 5-ASA was interrupted. 

        Each
patient was administered 60 ml of the composition according to example 8 rectally. 

        A
scintigraphic analysis was then carried out on the abdomen of the patients, kept in a prone position, respectively at 5, 30, 60, 120, 180 and 240 minutes from enema administration. 

        The
results obtained evidenced that in 11 out of 12 patients (92%) the enema went above the sigmoid colon and in 6 patients arrived up to the transverse colon. In said latter group about
19% of the total radioactivity was still found in the transverse colon. The average time employed by the formulation to get to the point farthest from the rectum was 4 hours (3 hours for
6 patients and 6 for the other half). 

 
 

Example 8    
    

	(Composition % w/v)
 
	 	 
	 
	mesalazine	 	6.67	%
	colloidal cellulose	 	1.40	%
	hydroxyethylcellulose	 	0.07	%
	sodium acetate trihydrate	 	1.08	%
	sodium metabisulphite	 	0.50	%
	EDTA disodium salt	 	0.10	%
	glacial acetic acid to pH 4.6	 	 	 
	water to 100 ml	 	 	 

 
 

Example 9    
    

	(Composition % w/v)
 
	 	 
	 
	mesalazine	 	3.33	%
	colloidal cellulose	 	1.20	%
	carboxypolymethylene	 	0.20	%
	sodium acetate trihydrate	 	1.08	%
	sodium metabisulphite	 	0.50	%
	EDTA disodium salt	 	0.10	%
	glacial acetic acid to pH 4.9	 	 	 
	water to 100 ml	 	 	 

 
 

Example 10    
    

	(Composition % w/v)
 
	 	 
	 
	mesalazine	 	6.67	%
	colloidal cellulose	 	1.60	%
	sodium carboxymethylcellulose	 	0.16	%
	sodium acetate trihydrate	 	1.08	%
	sodium metabisulphite	 	0.50	%
	EDTA disodium salt	 	0.10	%
	glacial acetic acid to pH 5.1	 	 	 
	water to 100 ml	 	 	 

 
 

Example 11    
    

	(Composition % w/v)
 
	 	 
	 
	mesalazine	 	3.33	%
	colloidal cellulose	 	1.30	%
	xantan gum	 	0.26	%
	sodium acetate trihydrate	 	1.08	%
	sodium metabisulphite	 	0.50	%
	EDTA disodium salt	 	0.10	%
	glacial acetic acid to pH 4.5	 	 	 
	water to 100 ml	 	 	 

 
 

Example 12    
    

	(Composition % w/v)
 
	 	 
	 
	mesalazine	 	6.67	%
	colloidal cellulose	 	1.50	%
	Hydroxypropylmethylcellulose	 	0.06	%
	sodium acetate trihydrate	 	1.08	%
	sodium metabisulphite	 	0.50	%
	EDTA disodium	 	0.10	%
	glacial acetic acid to pH 4.8	 	 	 
	water to 100 ml	 	 	 

 
 

Example 13    
    

	(Composition % w/v)
 
	 	 
	 
	mesalazine	 	3.33	%
	colloidal cellulose	 	1.30	%
	methylcellulose	 	0.10	%
	sodium acetate trihydrate	 	1.08	%
	sodium metabisulfite	 	0.50	%
	EDTA disodium	 	0.10	%
	glacial acetic to pH 4.7	 	 	 
	water to 100 ml	 	 	 

 
 

Example 14    
    

	(Composition % w/v)
 
	 	 
	 
	mesalazine	 	3.33	%
	colloidal cellulose	 	1.40	%
	xantan gum	 	0.21	%
	sodium acetate trihydrate	 	1.08	%
	sodium metabisulphite	 	0.50	%
	EDTA disodium salt	 	0.1	%
	glacial acetic acid to pH 4.6	 	 	 
	water to 60 ml	 	 	 

 
 

Example 15    
    

	(Composition % w/v)
 
	 	 
	 
	mesalazine	 	6.67	%
	colloidal cellulose	 	1.60	%
	carboxypolymethylene	 	0.32	%
	sodium acetate trihydrate	 	1.08	%
	sodium metabisulphite	 	0.50	%
	EDTA disodium salt	 	0.10	%
	glacial acetic acid to pH 4.8	 	 	 
	water to 100 ml	 	 	 

 
 

Example 16    
    

        Description of a pressure packaging containing an aluminum bag filled with the suspension of the invention. 

        Internal
volume of the packaging: 110 ml (external diameter: 35mm). Gas pressure inside (nitrogen): 9 atm. The bag made of thin aluminum foil is placed around the vertical axis of the 

actuator,
it occupies about 60% of the total inner volume of the container and is filled with 60 ml of the suspension of the invention. The outer side of the aluminum foil is covered with propylene,
the inner with polyethyleneterefialate. 

        We
claim: 

        1.     A
pharmaceutical composition in the form of an aqueous suspension, comprising mesalazine, colloidal cellulose in an amount between 1.2 to 1.6% w/v, and at least one
hydrophilic thickening agent, wherein said hydrophilic thickening agent is present in an amount of 0.048-0.32% w/v. 

        2.     The
pharmaceutical composition according to claim 1, wherein said hydrophilic thickening agent is present in a percentage by weight ratio to colloidal cellulose of
between 4 and 20%. 

        3.     The
pharmaceutical composition according to claim 1, further comprising one or more excipients selected from the group consisting of sequestrants, bacteriostatic agents,
antioxidants, buffering agents and inorganic acids. 

        4.     The
pharmaceutical composition according to claim 2. wherein the percentage by weight ratio of the hydrophilic thickening agent to colloidal cellulose is between 4 and
10%. 

        5.     The
pharmaceutical composition according to claim 1, wherein the percentage of colloidal cellulose is 1.4% w/v and the percentage by weight ratio of the hydrophilic
thickening agent to colloidal cellulose is between 6-7%. 

        6.     The
pharmaceutical composition according to claim 1, wherein the hydrophilic thickening agent is selected from the group consisting of carboxypolymethylene, sodium
carboxymethylcellulose, hydroxyethylcellulose, xantan gum, hydroxypropylmethylcellulose, methylcellulose, and carrageenam. 

        7.     The
pharmaceutical composition according to claim 6. wherein the hydrophilic thickening agent is hydroxyethylcellulose. 

        8.     The
pharmaceutical composition according to claim 1. wherein said composition is in a pressurized container which contains an inert gas as a propellant. 

        9.     The
pharmaceutical composition according to claim 8, wherein said composition is contained in a hermetically sealed bag inside the pressurized container. 

        10.   The
pharmaceutical composition according to claim 1, wherein the pH of the composition is between 4.5 and 5.1. 

        11.   The
pharmaceutical composition according to claim 1, wherein said composition exhibits the property of being stable at room temperature for a period of at least one
year. 

        12.   The
pharmaceutical composition according to claim 11, wherein said composition exhibits the property of being stable at
room temperature for a period of at least two years. 

        13.   The
pharmaceutical composition according to claim 1, wherein said composition is thixotropic. 

        14.   A
process for producing a stable pharmaceutical composition comprising mesalazine, colloidal cellulose in an amount between 1.2 to 1.6% w/v, and at least one hydrophilic
thickening agent, wherein said hydrophilic thickening agent is present in an amount of 0.048-0.32% w/v, comprising the steps of: 

        a)    dissolving
colloidal cellulose in an aliquot of distilled water. 

        b)    dissolving
a thickening agent in an aliquot of distilled water. 

        c)     mixing
said colloidal cellulose and said thickening agent to produce a suspension. 

        d)    adding
mesalazine to said suspension under vacuum while stirring. 

        e)    adding
distilled water to the suspension to obtain the final volume. 

        15.   A
method for treating ulcerative colitis, Crohn's disease or inflammatory bowel disease, comprising administering to a patient in need of such treatment an effective
amount of a pharmaceutical composition comprising mesalazine, colloidal cellulose in an amount between 1.2 to 1.6% w/v, and at least one hydrophilic thickening agent, wherein said hydrophilic
thickening agent is present in an amount of 0.048-0.32% w/v. 

        16.   The
method according to claim 14, wherein said colloidal cellulose is dissolved in an aliquot of distilled water which is
60% v/v of the total volume of distilled water to be used in said composition. 

        17.   The
method according to claim 14, wherein said thickening agent is dissolved in an aliqout of distilled water which is
30% v/v of the total volume of distilled water to be used in said composition. 

*
* * * * 

SCHEDULE 2.3  

 STATUS REPORTS ON PATENT APPLICATIONS  

SEE ATTACHED DOCUMENT 

	Invention Data	 	lunedi 7 ottobre 2002

Country Applications  

	Ctry
 
	 	Sub Case
	 	Case Type
	 	Status
	 	Application Number
	 	Filing Date
	 	Patent Number
	 	Issue Date

	IT	 	 	 	EPC	 	Granted	 	96110263.9	 	26-giu-1996	 	765664	 	03-apr-2002
	LU	 	 	 	EPC	 	Granted	 	96110263.9	 	26-giu-1996	 	765664	 	03-apr-2002
	EP	 	 	 	ORD	 	Nationized	 	96110263.9	 	26-giu-1996	 	765664	 	03-apr-2002
	IT	 	PRI	 	ORD	 	Granted	 	MI95A001987	 	28-set-1995	 	01277663	 	11-nov-1997
	JP	 	 	 	ORD	 	Pending	 	250402/96	 	20-set-1996	 	 	 	 
	US	 	 	 	ORD	 	Granted	 	08/722.720	 	30-set-1996	 	5731302	 	24-mar-1998
	GB	 	 	 	EPC	 	Granted	 	96110263.9	 	26-giu-1996	 	765664	 	03-apr-2002
	CH	 	 	 	EPC	 	Granted	 	96110263.9	 	26-giu-1996	 	765664	 	03-apr-2002
	ES	 	 	 	EPC	 	Granted	 	96110263.9	 	26-giu-1996	 	765664	 	03-apr-2002
	SE	 	 	 	EPC	 	Granted	 	96110263.9	 	26-giu-1996	 	765664	 	03-apr-2002
	PT	 	 	 	EPC	 	Granted	 	96110263.9	 	26-giu-1996	 	765664	 	03-apr-2002
	NL	 	 	 	EPC	 	Granted	 	96110263.9	 	26-giu-1996	 	765664	 	03-apr-2002
	IE	 	 	 	EPC	 	Granted	 	96110263.9	 	26-giu-1996	 	765664	 	03-apr-2002
	GR	 	 	 	EPC	 	Granted	 	96110263.9	 	26-giu-1996	 	765664	 	03-apr-2002
	FI	 	 	 	EPC	 	Granted	 	96110263.9	 	26-giu-1996	 	765664	 	03-apr-2002
	DK	 	 	 	EPC	 	Granted	 	96110263.9	 	26-giu-1996	 	765664	 	03-apr-2002
	BE	 	 	 	EPC	 	Granted	 	96110263.9	 	26-giu-1996	 	765664	 	03-apr-2002
	AT	 	 	 	EPC	 	Granted	 	96110263.9	 	26-giu-1996	 	765664	 	03-apr-2002
	DE	 	 	 	EPC	 	Granted	 	96110263.9	 	26-giu-1996	 	765664	 	03-apr-2002
	FR	 	 	 	EPC	 	Granted	 	96110263.9	 	26-giu-1996	 	765664	 	03-apr-2002

SCHEDULE 7.2  

 TERMS OF SUPPLY  

SEE ATTACHED DOCUMENT 

EP Spray System SA

Rue du Plan 30

CH-2002 Neuchâtel (Switzerland)  

	

Phone	
 	
0041 (0)32 727 62 62	
 	

 
	Fax	 	0041 (0)32 727 62 63	 	 
	Web Site	 	epspray.com	 	SIRTON PHARMACEUTICALS S.P.A.
	E-mail	 	epspray@epspray.com	 	PIAZZA XX SETTEMBRE, 2
	

VAT no.	
 	
162 506	
 	

IT-22079 VILLA GUARDIA (CO)
	

Customer no.	
 	

4114	
 	

 
	Your P.O. dated	 	27.05.2002	 	 
	Votre P.O. no.	 	49509/EG	 	 
	

Order confirmation no.	
 	

1323	
 	

 
	Delivery note no.	 	1323-B	 	 
	Person of contact	 	CELINE FELLAY	 	Neuchâtel, 26 juillet 2002

Invoice no. 2782 

	Our part no.
 
	 	Your part no.
	 	Description
	 	Quantity
	 	Price

/1000
	 	Amount CHF

VAT not incl.

	6027/A6:02	 	5220015	 	VALVE POUCH 63ML, ALU 35X125	 	150.000	 	333,00	 	49.950,00
	7119*07	 	5220040	 	ACTUATOR CLIP	 	150.000	 	71,00	 	10.650,00
	7812	 	5220027	 	VAPO CAP + VAPO RING ASSEMBLED	 	150.000	 	65,00	 	9.750,00

        THE
EXPORTER OF THE PRODUCTS COVERED BY THIS DOCUMENT (CUSTOMS AUTORISATION NO 1542/1989) DECLARES THAT, EXCEPT WHERE OTHERWISE CLEARLY INDICATED, THESE PRODUCTS ARE OF SWISS
PREFERENTIAL ORIGIN. 

	CELINE FELLAY	 	NEUCHATEL,	 	July 26, 2002	 	 

        [SEAL]

	DOGANA di COMO [ILLEGIBLE] I.V.A. RISCOSSI

su BOLLA IMPORTAZIONE	 	 	 	  

  

/s/ Celine Fellay
	N.	 	/s/ [ILLEGIBLE]
	 	 	 	EP SPRAY SYSTEM SA
	del	 	    
	 	31 LUG. 2002	 	2002 Neuchâtel
	 	 	IL FUNZIONARIO	 	 	 	 

	
 Value of the goods
 
	
 	

Postage + packing
	
 	

Net price
	
 	

 
	
 	

Total in CHF

	70.350,00	 	0,00	 	70.350,00	 	 	 	70.350,00

	
 Delivery conditions
 
	
 	

Payment terms
	
 	

Delivery address
	
 	

Bank references

	EX WORKS	 	VIREMENT

WITHIN 60 DAYS NETTO	 	SIRTON PHARMACEUTICALS S.P.A

PIAZZA XX SETTEMBRE, 2	 	Crédit Suisse

CH-2000 Neuchâtel
	

 	
 	

 	
 	

IT-22079 VILLA GUARDIA (CO)	
 	

Compte 4531-604557-31

 
 

SCHEDULE 11    
    
    ASSIGNMENT AGREEMENT    
    

SEE
ATTACHED DOCUMENT 

UNITED STATES OF AMERICA  

  
 

    ASSIGNMENT    
    

        In consideration of one dollar, paid to us by AXCAN PHARMA INC., whose full post office address is 597, boul. Laurier, Mont St-Hilaire
(Québec) J3H 6C4 Canada, receipt of which is hereby acknowledged, and other good and valuable considerations, the undersigned, Gentium S.p.A, whose full post office address is
Piazza XX Settembre n. 2, 22079 Villa Guardia (Como), Italy, does hereby sell and assign (and confirm such sale and assignment) to AXCAN PHARMA INC. all its right, title and interest in the
United States of America, in and to the invention entitled STABLE AQUEOUS SUSPENSION[S] OF MESALAZINE as fully described and claimed in the United States patent no. US
5,731,302 and any corresponding patent applications including, without limitation, continuation applications, continuation-in-part applications and divisional applications, and
any patents which may issue therefor and any patents which may be reissued, re-examined or extended therefrom. 

	  	 	SIGNED this	 	 	 	day of	 	 	 	 
	 	 	 	 	
 (day)	 	 	 	
 (month)	 	
 (year)
	

at	
 	

 (City)
                                         
       (Province)
                                         
       (Country)
	

                        	
 	

 	
 	

 	
 	

 	
 	

 	
 	

 

	WITNESSES	 	GENTIUM S.P.A
	 	 	Per:
	

 Full name:	
 	

 
	

 	
 	

 Name:

Title:
	

 Full name:	
 	

 

 
 

READ AND APPROVED    
    

	  	 	SIGNED this	 	 	 	day of	 	 	 	 
	 	 	 	 	
 (day)	 	 	 	
 (month)	 	
 (year)
	

at	
 	

 (City)
                                         
       (Province)
                                         
       (Country)
	

                        	
 	

 	
 	

 	
 	

 	
 	

 	
 	

 

	 	 	AXCAN PHARMA INC.
	 	 	Per:
	

 	
 	

/s/  [ILLEGIBLE]      
 Name:

Tile:

QuickLinks

Exhibit 10.18

PURCHASE AGREEMENT BY AND BETWEEN SIRTON PHARMACEUTICALS S.p.A. AND GENTIUM S.p.A AND AXCAN PHARMA INC. October 9, 2002

TABLE OF CONTENTS

EXECUTION COPY

PURCHASE AGREEMENT

PREAMBLE

Signature page 1 of 1

SIGNATURES

SCHEDULE 1.1.2 COMMERCIAL ADVANTAGES

SEE ATTACHED DOCUMENT

SCHEDULE 1.1.4 EUROPEAN COUNTRIES SEE ATTACHED DOCUMENT

RIASSUNTO POLITICO-STATISTICO

SCHEDULE 1.1.5 GEL FORMULATION SEE ATTACHED DOCUMENT

PARTE II B PROCEDIMENTO DI FABBRICAZIONE

SCHEDULE 1.1.12 PATENTS

SEE ATTACHED DOCUMENT

SCHEDULE 1.1.13 PURCHASED PATENTS SEE ATTACHED DOCUMENT

17 Claims, No Drawings

STABLE AQUEOUS SUSPENSIONS OF MESALAZINE

TABLE I

TABLE II

BRIEF DESCRIPTION OF THE DRAWINGS

TABLE III

TABLE IV

Example 1

Example 2

Example 3

Example 4

Example 5

Example 6

Example 7

Example 8

Example 9

Example 10

Example 11

Example 12

Example 13

Example 14

Example 15

Example 16

SCHEDULE 11 ASSIGNMENT AGREEMENT

ASSIGNMENT

READ AND APPROVED

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00077-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00077-of-00352.parquet"}]]